Bristol-Myers Squibb (BMY) 10-Q 26 Jul 24 2024 Q2 Quarterly report Financial data

COVER

COVER - shares	6 Months Ended
	Jun. 30, 2024	Jul. 19, 2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-01136
Entity Registrant Name	BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-0790350
Entity Address, Address Line One	Route 206 & Province Line Road
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08543
City Area Code	609
Local Phone Number	252-4621
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,027,395,178
Entity Central Index Key	0000014272
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Small Business	false
Common Stock $0.10 Par Value
Title of 12(b) Security	Common Stock, $0.10 Par Value
Trading Symbol	BMY
Security Exchange Name	NYSE
1.000% Notes due 2025
Title of 12(b) Security	1.000% Notes due 2025
Trading Symbol	BMY25
Security Exchange Name	NYSE
1.750% Notes due 2035
Title of 12(b) Security	1.750% Notes due 2035
Trading Symbol	BMY35
Security Exchange Name	NYSE
Celgene Contingent Value Rights
Title of 12(b) Security	Celgene Contingent Value Rights
Trading Symbol	CELG RT
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total Revenues		$ 12,201	$ 11,226	$ 24,066	$ 22,563
Cost of products sold	[1]	3,267	2,876	6,199	5,442
Marketing, selling and administrative		1,928	1,934	4,295	3,696
Research and development		2,899	2,258	5,594	4,579
Acquired IPRD		132	158	13,081	233
Amortization of acquired intangible assets		2,416	2,257	4,773	4,513
Other (income)/expense, net		273	(116)	354	(529)
Total Expenses		10,915	9,367	34,296	17,934
Earnings/(loss) before income taxes		1,286	1,859	(10,230)	4,629
Income tax (benefit)/provision		(398)	(218)	(6)	285
Net earnings/(loss)		1,684	2,077	(10,224)	4,344
Noncontrolling interest		4	4	7	9
Net earnings/(loss) attributable to BMS		$ 1,680	$ 2,073	$ (10,231)	$ 4,335
Earnings/(Loss) per common share:
Basic (usd per share)		$ 0.83	$ 0.99	$ (5.05)	$ 2.07
Diluted (usd per share)		$ 0.83	$ 0.99	$ (5.05)	$ 2.06
Net product sales
Total Revenues		$ 11,925	$ 10,917	$ 23,484	$ 21,965
Alliance and other revenues
Total Revenues		$ 276	$ 309	$ 582	$ 598
[1]Excludes amortization of acquired intangible assets

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net earnings/(loss)	$ 1,684	$ 2,077	$ (10,224)	$ 4,344
Other comprehensive income/(loss), net of taxes and reclassifications to earnings:
Derivatives qualifying as cash flow hedges	54	3	245	(121)
Pension and postretirement benefits	(64)	(11)	(51)	(11)
Marketable debt securities	0	0	(2)	0
Foreign currency translation	(46)	(11)	(102)	26
Total Other Comprehensive Income/(Loss)	(56)	(19)	90	(106)
Comprehensive income/(loss)	1,628	2,058	(10,134)	4,238
Comprehensive income attributable to noncontrolling interest	4	4	7	9
Comprehensive income/(loss) attributable to BMS	$ 1,624	$ 2,054	$ (10,141)	$ 4,229

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,293	$ 11,464
Marketable debt securities	360	816
Receivables	11,423	10,921
Inventories	3,077	2,662
Other current assets	5,737	5,907
Total Current assets	26,890	31,770
Property, plant and equipment	6,845	6,646
Goodwill	21,732	21,169
Other intangible assets	29,428	27,072
Deferred income taxes	3,323	2,768
Marketable debt securities	357	364
Other non-current assets	6,071	5,370
Total Assets	94,646	95,159
Current liabilities:
Short-term debt obligations	3,531	3,119
Accounts payable	3,751	3,259
Other current liabilities	15,983	15,884
Total Current liabilities	23,265	22,262
Deferred income taxes	461	338
Long-term debt	48,858	36,653
Other non-current liabilities	4,993	6,421
Total Liabilities	77,577	65,674
Commitments and Contingencies
BMS Shareholders’ equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	45,766	45,684
Accumulated other comprehensive loss	(1,456)	(1,546)
Retained earnings	16,103	28,766
Less cost of treasury stock	(43,690)	(43,766)
Total BMS Shareholders’ Equity	17,015	29,430
Noncontrolling interest	54	55
Total Equity	17,069	29,485
Total Liabilities and Equity	$ 94,646	$ 95,159

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows From Operating Activities:
Net earnings/(loss)	$ (10,224)	$ 4,344
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization, net	5,128	4,861
Deferred income taxes	(1,042)	(1,634)
Stock-based compensation	258	259
Impairment charges	871	67
Divestiture gains and royalties	(550)	(417)
Acquired IPRD	13,081	233
Equity investment (gains)/losses	(209)	213
Other adjustments	20	(9)
Changes in operating assets and liabilities:
Receivables	(540)	(240)
Inventories	(443)	(298)
Accounts payable	41	22
Rebates and discounts	70	(418)
Income taxes payable	(1,033)	(1,235)
Other	(268)	(891)
Net cash provided by operating activities	5,160	4,857
Cash Flows From Investing Activities:
Sale and maturities of marketable debt securities	822	327
Purchase of marketable debt securities	(358)	(555)
Proceeds from sales of equity investments	60	67
Capital expenditures	(546)	(537)
Divestiture and other proceeds	511	421
Acquisition and other payments, net of cash acquired	(21,426)	(262)
Net cash used in investing activities	(20,937)	(539)
Cash Flows From Financing Activities:
Proceeds from issuance of short-term debt obligations	2,987	0
Repayments of short-term debt obligations	(2,731)	0
Other short-term financing obligations, net	409	243
Proceeds from issuance of long-term debt	12,883	0
Repayments of long-term debt	(395)	(1,879)
Repurchase of common stock	0	(1,155)
Dividends	(2,429)	(2,393)
Stock option proceeds and other, net	(103)	(39)
Net cash provided by/(used in) financing activities	10,621	(5,223)
Effect of exchange rates on cash, cash equivalents and restricted cash	(67)	5
Decrease in cash, cash equivalents and restricted cash	(5,223)	(900)
Cash, cash equivalents and restricted cash at beginning of period	11,519	9,325
Cash, cash equivalents and restricted cash at end of period	$ 6,296	$ 8,425

BASIS OF PRESENTATION AND RECEN

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS	BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS Basis of Consolidation Bristol-Myers Squibb Company ("BMS", "we", "our", "us" or "the Company") prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position of the Company as of June 30, 2024 and December 31, 2023 and the results of operations for the three and six months ended June 30, 2024 and 2023, and cash flows for the six months ended June 30, 2024 and 2023. All intercompany balances and transactions have been eliminated. These consolidated financial statements and the related footnotes should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023 included in the 2023 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS's operational structure, the Chief Executive Officer ("CEO"), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see "—Note 2. Revenue". Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of intangible assets; charge-backs, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates. Recently Issued Accounting Standards Not Yet Adopted Income Taxes In December 2023, the FASB issued amended guidance on income tax disclosures. The guidance is intended to provide additional disaggregation to the effective income tax rate reconciliation and income tax payment disclosures. The amended guidance is effective for annual periods beginning January 1, 2025 and should be applied on a prospective basis. Early adoption is permitted. Segment Reporting In November 2023, the FASB issued amended guidance for improvements to reportable segment disclosures. The revised guidance requires that a public entity disclose significant segment expenses regularly reviewed by the chief operating decision maker (CODM), including public entities with a single reportable segment. The amended guidance is effective for fiscal years beginning January 1, 2024 and interim periods beginning January 1, 2025 and should be applied on a retrospective basis. Early adoption is permitted.

REVENUE

REVENUE	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE The following table summarizes the disaggregation of revenue by nature: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Net product sales $ 11,925 $ 10,917 $ 23,484 $ 21,965 Alliance revenues 116 179 250 323 Other revenues 160 130 332 275 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563 The following table summarizes GTN adjustments: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Gross product sales $ 20,780 $ 18,111 $ 40,075 $ 35,399 GTN adjustments (a) Charge-backs and cash discounts (2,843) (2,279) (5,399) (4,370) Medicaid and Medicare rebates (3,864) (3,143) (6,948) (5,625) Other rebates, returns, discounts and adjustments (2,148) (1,772) (4,244) (3,439) Total GTN adjustments (b) (8,855) (7,194) (16,591) (13,434) Net product sales $ 11,925 $ 10,917 $ 23,484 $ 21,965 (a) Includes reductions/(increases) to GTN adjustments for product sales made in prior periods resulting from changes in estimates of ($19 million) and $61 million for the three and six months ended June 30, 2024 and $11 million and $98 million for the three and six months ended June 30, 2023, respectively. (b) Includes U.S. GTN adjustments of $8.0 billion and $14.9 billion for the three and six months ended June 30, 2024 and $6.4 billion and $11.9 billion for the three and six months ended June 30, 2023, respectively. The following table summarizes the disaggregation of revenue by product and region: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Growth Portfolio Opdivo $ 2,387 $ 2,145 4,465 $ 4,347 Orencia 948 927 1,746 1,691 Yervoy 630 585 1,213 1,093 Reblozyl 425 234 779 440 Opdualag 235 154 441 271 Abecma 95 132 177 279 Zeposia 151 100 261 178 Breyanzi 153 100 260 171 Camzyos 139 46 223 75 Sotyktu 53 25 97 41 Augtyro 7 — 13 — Krazati 32 — 53 — Other Growth products (a) 341 295 660 575 Total Growth Portfolio 5,596 4,743 10,388 9,161 Legacy Portfolio Eliquis 3,416 3,204 7,136 6,627 Revlimid 1,353 1,468 3,022 3,218 Pomalyst/Imnovid 959 847 1,824 1,679 Sprycel 424 458 798 887 Abraxane 231 258 448 497 Other Legacy products (b) 222 248 450 494 Total Legacy Portfolio 6,605 6,483 13,678 13,402 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563 United States $ 8,801 $ 7,804 $ 17,277 $ 15,756 International 3,224 3,247 6,414 6,477 Other (c) 176 175 375 330 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563 (a) Includes Onureg , Inrebic , Nulojix , Empliciti and royalty revenues. (b) Includes other mature brands. (c) Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations. Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation. Revenue recognized from performance obligations satisfied in prior periods was $76 million and $258 million for the three and six months ended June 30, 2024 and $75 million and $241 million for the three and six months ended June 30, 2023, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.

ALLIANCES

ALLIANCES	6 Months Ended
	Jun. 30, 2024
ALLIANCES [Abstract]
ALLIANCES	ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS refers to these collaborations as alliances, and its partners as alliance partners. Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Revenues from alliances Net product sales $ 3,470 $ 3,320 $ 7,232 $ 6,852 Alliance revenues 116 179 250 323 Total alliance revenues $ 3,586 $ 3,499 $ 7,482 $ 7,175 To/(from) alliance partners Cost of products sold $ 1,692 $ 1,614 $ 3,517 $ 3,320 Marketing, selling and administrative (65) (64) (144) (138) Research and development 46 36 100 80 Acquired IPRD 80 55 880 55 Other (income)/expense, net (102) (15) (114) (27) Dollars in millions June 30, December 31, Selected alliance balance sheet information Receivables – from alliance partners $ 290 $ 233 Accounts payable – to alliance partners 1,627 1,394 Deferred income – from alliances (a) 248 274 (a) Includes unamortized upfront and milestone payments. The nature, purpose, significant rights and obligations of the parties and specific accounting policy elections for each of the Company's significant alliances are discussed in the 2023 Form 10-K. Significant developments and updates related to alliances during the six months ended June 30, 2024 and 2023 are set forth below. SystImmune BMS and SystImmune, Inc. ("SystImmune") are parties to a global strategic collaboration for the co-development and co-commercialization of BL-B01D1, a bispecific topoisomerase inhibitor-based anti-body drug conjugate, which is currently being evaluated in a Phase I clinical trial for metastatic or unresectable NSCLC and is also in development for breast cancer and other tumor types. BMS paid an upfront fee of $800 million, which was included in Acquired IPRD during the six months ended June 30, 2024. BMS is also obligated to pay up to $7.6 billion upon the achievement of contingent development, regulatory and sales-based milestones. The parties will jointly develop and commercialize BL-B01D1 in the U.S. and share in the profits and losses. SystImmune will be responsible for the development, commercialization, and manufacturing in Mainland China and will be responsible for manufacturing certain drug supplies for outside of Mainland China, where BMS will receive a royalty on net sales. BMS will be responsible for the development and commercialization in the rest of the world, where SystImmune will receive a royalty on net sales. Eisai In June 2024, BMS and Eisai agreed to end the global strategic collaboration for the co-development and co-commercialization of MORAb-202 due to the ongoing portfolio prioritization efforts within BMS. All rights and obligations for MORAb-202 were transferred to Eisai and BMS will receive $90 million as part of the termination, which was included in Other (income)/expense, net during the three months ended June 30, 2024.

ACQUISITIONS, DIVESTITURES, LIC

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS	6 Months Ended
	Jun. 30, 2024
Acquisitions, Divestitures and Other Arrangements [Abstract]
ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS	ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS Divestitures The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses). Three Months Ended June 30, Net Proceeds Divestiture (Gains)/Losses Royalty Income Dollars in millions 2024 2023 2024 2023 2024 2023 Diabetes business - royalties $ 265 $ 185 $ — $ — $ (265) $ (218) Mature products and other — 3 — — — — Total $ 265 $ 188 — $ — $ (265) (218) Six Months Ended June 30, Net Proceeds Divestiture (Gains)/Losses Royalty Income Dollars in millions 2024 2023 2024 2023 2024 2023 Diabetes business - royalties $ 496 $ 401 $ — $ — $ (536) $ (406) Mature products and other — 7 — — — — Total $ 496 $ 408 — $ — $ (536) (406) Licensing and Other Arrangements The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Keytruda * royalties $ (137) $ (284) $ (270) $ (563) Tecentriq * royalties (11) (24) (23) (54) Contingent milestone income (25) (5) (25) (36) Amortization of deferred income (12) (15) (24) (27) Other royalties and licensing income (6) (12) (10) (23) Royalty and licensing income $ (191) $ (340) $ (352) $ (703) Keytruda* Patent License Agreement BMS and Ono are parties to a global patent license agreement with Merck related to Merck's PD-1 antibody Keytruda *. Under the agreement, Merck paid ongoing royalties on global sales of Keytruda

OTHER (INCOME)_EXPENSE, NET

OTHER (INCOME)/EXPENSE, NET	6 Months Ended
	Jun. 30, 2024
Other Nonoperating Income (Expense) [Abstract]
OTHER (INCOME)/EXPENSE, NET	OTHER (INCOME)/EXPENSE, NET Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Interest expense (Note 10) $ 521 $ 282 $ 946 $ 570 Royalty and licensing income (Note 4) (191) (340) (352) (703) Royalty income - divestiture (Note 4) (265) (218) (536) (406) Investment income (87) (95) (270) (197) Litigation and other settlements (a) 69 (7) 71 (332) Provision for restructuring (Note 6) 260 113 480 180 Integration expenses (Note 6) 74 59 145 126 Equity investment (gain)/losses (Note 9) (107) 58 (209) 213 Acquisition expense (Note 4) 1 — 50 — Other (2) 32 29 20 Other (income)/expense, net $ 273 $ (116) $ 354 $ (529) (a) Includes $90 million of income related to the Eisai collaboration termination incurred during the three months ended June 30, 2024 and $400 million of income related to Nimbus' TYK2 program change of control provision incurred during the six months ended June, 30 2023.

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Jun. 30, 2024
Restructuring Charges [Abstract]
RESTRUCTURING	RESTRUCTURING 2023 Restructuring Plan In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities. Consistent with our prioritization and efficiency goals communicated earlier this year, BMS continues to execute on strategic productivity initiatives through portfolio prioritization and management of our operating costs. Total expected restructuring costs under the 2023 Restructuring Plan to be incurred through 2026 are approximately $1.5 billion. These costs consist primarily of employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment. Celgene and Other Acquisition Plans Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). The remaining charges of approximately $400 million consist primarily of employee termination costs, IT system integration costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment. The following provides the charges related to restructuring initiatives by type of cost: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 2023 Restructuring Plan $ 264 $ 170 $ 332 $ 231 Celgene and Other Acquisition Plans 93 64 337 138 Total charges $ 357 $ 234 $ 669 $ 369 Employee termination costs $ 260 $ 109 $ 477 $ 174 Other termination costs — 4 3 6 Provision for restructuring 260 113 480 180 Integration expenses 74 59 145 126 Accelerated depreciation 20 12 34 13 Asset impairments — 50 2 50 Other shutdown costs 3 — 8 — Total charges $ 357 $ 234 $ 669 $ 369 Cost of products sold $ 3 $ 36 $ 17 $ 37 Marketing, selling and administrative 6 20 12 20 Research and development 14 6 15 6 Other (income)/expense, net 334 172 625 306 Total charges $ 357 $ 234 $ 669 $ 369 The following summarizes the charges and spending related to restructuring plan activities: Six Months Ended June 30, Dollars in millions 2024 2023 Beginning balance $ 188 $ 47 Provision for restructuring 480 180 Foreign currency translation and other (3) 1 Payments (234) (48) Ending balance $ 431 $ 180

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Earnings/(Loss) before income taxes $ 1,286 $ 1,859 $ (10,230) $ 4,629 Income tax (benefit)/provision (398) (218) (6) 285 Effective tax rate (30.9) % (11.7) % 0.1 % 6.2 % Provision for income taxes in interim periods is determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The effective tax rate for the three months ended June 30, 2024 was primarily impacted by the release of income tax reserves of $644 million related to the resolution of Celgene's 2017-2019 IRS audit and jurisdictional earnings mix resulting from amortization of acquired intangible assets. The effective tax rate for the six months ended June 30, 2024 was impacted by a $12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna, as well as the aforementioned income tax reserve releases and jurisdictional earnings mix resulting from amortization of acquired intangible assets. The effective tax rate during the three and six months ended June 30, 2023 was primarily impacted by a $656 million deferred income tax benefit following the receipt of a non-U.S. tax ruling regarding the deductibility of a statutory impairment of subsidiary investments. In addition, the effective tax rate during the six months ended June 30, 2023 was impacted by jurisdictional earnings mix resulting from amortization of acquired intangible assets, equity investment losses, litigation and other settlements, as well as releases of income tax reserves of $89 million related to the resolution of Celgene's 2009-2011 IRS audits. Additional changes to the effective tax rate may occur in future periods due to various reasons, including changes to the estimated pretax earnings mix and tax reserves and revised interpretations or changes to the tax legislation code. During the six months ended June 30, 2024 and 2023, income tax payments were $2.1 billion and $3.1 billion, including $799 million and $567 million, respectively, for the transition tax following the TCJA enactment. BMS is currently under examination by a number of tax authorities that proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. As previously disclosed, BMS received several notices of proposed adjustments from the IRS related to transfer pricing and other tax issues for the 2008 to 2012 tax years. BMS disagrees with the IRS's positions and continues to work cooperatively with the IRS to resolve these issues. In the fourth quarter of 2022, BMS entered the IRS administrative appeals process to resolve these matters. Timing of the final resolution of these complex matters is uncertain and could have a material impact on BMS's consolidated financial statements. It is reasonably possible that the amount of unrecognized tax benefits as of June 30, 2024 could decrease in the range of approximately $110 million to $150 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. It is reasonably possible that new issues will be raised by tax authorities that may increase unrecognized tax benefits, however, an estimate of such increases cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by jurisdiction.

EARNINGS_(LOSS) PER SHARE

EARNINGS/(LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
EARNINGS/(LOSS) PER SHARE	EARNINGS/(LOSS) PER SHARE Three Months Ended June 30, Six Months Ended June 30, Dollars in millions, except per share data 2024 2023 2024 2023 Net earnings/(loss) attributable to BMS $ 1,680 $ 2,073 $ (10,231) $ 4,335 Weighted-average common shares outstanding – basic 2,027 2,093 2,025 2,096 Incremental shares attributable to share-based compensation plans 2 9 — 11 Weighted-average common shares outstanding – diluted 2,029 2,102 2,025 2,107 Earnings/(Loss) per common share Basic $ 0.83 $ 0.99 $ (5.05) $ 2.07 Diluted 0.83 0.99 (5.05) 2.06 The total number of potential shares of common stock excluded from the diluted (loss)/earnings per common share computation because of the antidilutive impact was 39 million and 44 million for the three and six months ended June 30, 2024, respectively, and not material for the three and six months ended June 30, 2023.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below: June 30, 2024 December 31, 2023 Dollars in millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents Money market and other securities $ — $ 4,004 $ — $ — $ 8,489 $ — Marketable debt securities Certificates of deposit — 201 — — 609 — Commercial paper — — — — 92 — Corporate debt securities — 475 — — 460 — U.S. Treasury securities — 41 — — 19 — Derivative assets — 456 — — 219 — Equity investments 494 99 — 318 141 — Derivative liabilities — 114 — — 160 — Contingent consideration liability Contingent value rights (a) 2 — 248 4 — — Other acquisition related contingent consideration — — — — — 8 (a) Includes the fair value of contingent value rights associated with the Mirati acquisition as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements." The fair value of the contingent value rights was estimated using a probability-weighted expected return method. As further described in "Item 8. Financial Statements and Supplementary Data—Note 9. Financial Instruments and Fair Value Measurements" in the Company's 2023 Form 10-K, the Company's fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs); (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs); or (3) unobservable inputs (Level 3 inputs). The fair value of Level 2 equity investments is adjusted for characteristics specific to the security and is not adjusted for contractual sale restrictions. Equity investments subject to contractual sale restrictions were not material as of June 30, 2024 and December 31, 2023. Marketable Debt Securities The amortized cost for marketable debt securities approximates its fair value and these securities mature within five years as of June 30, 2024, and four years as of December 31, 2023. Equity Investments The following summarizes the carrying amount of equity investments: Dollars in millions June 30, December 31, Equity investments with readily determinable fair values $ 593 $ 459 Equity investments without readily determinable fair values 785 698 Limited partnerships and other equity method investments 622 542 Total equity investments $ 2,000 $ 1,699 The following summarizes the activity related to equity investments. Changes in fair value of equity investments are included in Other (income)/expense, net. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Equity investments with RDFV Net (gain)/loss recognized $ (36) $ 47 (122) 188 Less: net (gain)/loss recognized on investments sold — (11) 1 (12) Net unrealized (gain)/loss recognized on investments still held (36) 58 (123) 200 Equity investments without RDFV Upward adjustments (11) — (21) (6) Net realized (gain)/loss recognized on investments sold (36) — (36) — Impairments and downward adjustments 4 — 29 — Equity in net (income)/loss of affiliates (28) 11 (59) 31 Total equity investment (gains)/losses $ (107) $ 58 (209) 213 Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of June 30, 2024 were $207 million and $85 million, respectively. Qualifying Hedges and Non-Qualifying Derivatives Cash Flow Hedges BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales, third party sales and certain other foreign currency transactions. The objective of these foreign exchange contracts is to reduce variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro and Japanese yen. The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the consolidated balance sheets. Changes in fair value for these foreign exchange contracts, which are designated as cash flow hedges, are temporarily recorded in Accumulated other comprehensive loss ("AOCL") and reclassified to net earnings when the hedged item affects earnings (typically within the next 24 months). As of June 30, 2024, assuming market rates remain constant through contract maturities, we expect to reclassify pre-tax gains of $80 million into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $4.2 billion for the euro contracts and $1.2 billion for Japanese yen contracts as of June 30, 2024. BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. The unrealized gains and losses on these contracts are reported in AOCL and reclassified to Other (income)/expense, net, in the same periods during which the hedged debt affects earnings. The notional amount of cross-currency swap contracts associated with long-term debt denominated in euros was $1.2 billion as of June 30, 2024. In January 2024, BMS entered into forward interest rate contracts of a total notional value of $5.0 billion to hedge future interest rate risk associated with the unsecured senior notes issued in February 2024. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senior notes. The $131 million gain on the transaction was included in Other Comprehensive (Loss)/Income and will be amortized as a reduction to interest expense over the term of the related debt. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring within 60 days after the originally forecasted date or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. Foreign currency exchange contracts not designated as a cash flow hedge offset exposures in certain foreign currency denominated assets, liabilities and earnings. Changes in the fair value of these derivatives are recognized in earnings as they occur. Net Investment Hedges Cross-currency swap contracts and foreign currency forward contracts of $1.6 billion as of June 30, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $660 million and euro of $593 million as of June 30, 2024. During the three months ended March 31, 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of €375 million. The related net investment hedge was entered into to hedge euro currency exposures of the net investment in certain foreign affiliates and was recognized in Long-term debt. The effective portion of foreign exchange gain or loss on the remeasurement of debt denominated in euros was included in the foreign currency translation component of AOCL with the related offset in Long-term debt. During the three and six months ended June 30, 2024, the amortization of gains related to the portion of our net investment hedges that was excluded from the assessment of effectiveness was not material. Fair Value Hedges Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value . Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability in the consolidated balance sheets. As a result, there was no net impact in earnings. If the underlying swap is terminated prior to maturity, then the fair value adjustment to the underlying debt is amortized as a reduction to interest expense over the remaining term of the debt. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in investing activities. The following table summarizes the fair value and the notional values of outstanding derivatives: June 30, 2024 December 31, 2023 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Designated as cash flow hedges Foreign currency exchange contracts $ 6,115 $ 256 $ 403 $ (8) $ 4,772 $ 130 $ 1,971 $ (66) Cross-currency swap contracts 583 24 627 (8) 1,210 50 — — Designated as net investment hedges Foreign currency exchange contracts 505 36 377 (2) — — 215 (8) Cross-currency swap contracts 396 29 292 (13) — — 747 (43) Designated as fair value hedges Interest rate swap contracts 1,000 1 2,255 (18) 2,500 3 1,755 (14) Not designated as hedges Foreign currency exchange contracts 3,122 103 1,749 (65) 906 20 1,250 (29) Total return swap contracts (c) $ 441 $ 7 $ — $ — $ 401 $ 16 $ — $ — (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities. (c) Total return swap contracts hedge changes in fair value of certain deferred compensation liabilities. The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedges: Three Months Ended June 30, 2024 Six Months Ended June 30, 2024 Dollars in millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Foreign currency exchange contracts $ (29) $ (40) $ (74) $ (53) Cross-currency swap contracts — 7 — 36 Interest rate swap contracts — 4 — 7 Forward interest rate contracts — (1) — (2) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Dollars in millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Foreign currency exchange contracts $ (90) $ (44) $ (210) $ (60) Cross-currency swap contracts — (5) — (28) Interest rate swap contracts — (4) — (7) The following table summarizes the effect of derivative and non-derivative instruments designated as hedges in Other comprehensive income: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Derivatives designated as cash flow hedges Foreign exchange contracts gain/(loss): Recognized in Other comprehensive (loss)/income $ 102 $ 60 $ 241 $ 53 Reclassified to Cost of products sold (29) (90) (74) (210) Cross-currency swap contracts gain/(loss): Recognized in Other comprehensive (loss)/income (18) 34 (34) 28 Reclassified to Other (income)/expense, net 10 4 41 (9) Forward interest rate contract gain/(loss): Recognized in Other comprehensive (loss)/income — — 131 — Reclassified to Other (income)/expense, net (1) — (2) — Derivatives designated as net investment hedges Cross-currency swap contracts gain/(loss): Recognized in Other comprehensive (loss)/income 23 34 50 35 Foreign exchange contracts gain/(loss): Recognized in Other comprehensive (loss)/income 18 — 41 — Non-derivatives designated as net investment hedges Non-U.S. dollar borrowings gain/(loss): Recognized in Other comprehensive (loss)/income — — — (10)

FINANCING ARRANGEMENTS

FINANCING ARRANGEMENTS	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS Short-term debt obligations include: Dollars in millions June 30, December 31, Commercial paper borrowings $ 266 $ — Non-U.S. short-term financing obligations 173 170 Current portion of Long-term debt 3,092 2,873 Other — 76 Short-term debt obligations $ 3,531 $ 3,119 BMS may issue a maximum of $7.0 billion of unsecured notes with maturities of not more than 365 days from the date of issuance under its commercial paper program. During the first quarter of 2024, $3.0 billion of commercial paper was issued and $2.7 billion of it was repaid during the second quarter of 2024. The weighted-average effective borrowing rate on the outstanding commercial paper borrowings was 5.43% as of June 30, 2024. Long-term debt and the current portion of Long-term debt include: Dollars in millions June 30, December 31, Principal value $ 51,449 $ 38,886 Adjustments to principal value: Fair value of interest rate swap contracts (17) (11) Unamortized basis adjustment from swap terminations 76 82 Unamortized bond discounts and issuance costs (405) (303) Unamortized purchase price adjustments of Celgene debt 847 872 Total $ 51,950 $ 39,526 Current portion of Long-term debt $ 3,092 $ 2,873 Long-term debt 48,858 36,653 Total $ 51,950 $ 39,526 The fair value of Long-term debt was $47.7 billion as of June 30, 2024 and $36.7 billion as of December 31, 2023 valued using Level 2 inputs, which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments. During the first quarter of 2024, BMS issued an aggregate principal amount of $13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $12.9 billion, consisting of: Principal Amount (in millions) Floating rate notes due 2026 (a) $ 500 4.950% Notes due 2026 1,000 4.900% Notes due 2027 1,000 4.900% Notes due 2029 1,750 5.100% Notes due 2031 1,250 5.200% Notes due 2034 2,500 5.500% Notes due 2044 500 5.550% Notes due 2054 2,750 5.650% Notes due 2064 1,750 Total $ 13,000 (a) As of June 30, 2024, floating rate equals SOFR+0.49%. The Company used the net proceeds from this offering to partially fund the acquisitions of RayzeBio and Karuna (see "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information) and used the remaining net proceeds for general corporate purposes. In connection with the issuance of the 2024 Senior Unsecured Notes, the Company terminated the $10.0 billion 364-day senior unsecured delayed draw term loan facility, which was entered into in February 2024 to provide bridge financing for the RayzeBio and Karuna acquisitions. During the six months ended June 30, 2024, $395 million 3.625% Notes matured and were repaid. During the six months ended June 30, 2023, $1.9 billion of debt matured and was repaid, including $750 million 2.750% Notes, $890 million 3.250% Notes and $239 million 7.150% Notes. Interest payments were $735 million and $639 million for the six months ended June 30, 2024 and 2023, respectively, net of amounts related to interest rate swap contracts. Credit Facilities As of June 30, 2024, BMS had a five-year $5.0 billion revolving credit facility expiring in January 2029, extendable annually by one year with the consent of the lenders and a $2.0 billion 364-day revolving credit facility expiring in January 2025. The facilities provide for customary terms and conditions with no financial covenants and are used to provide backup liquidity for our commercial paper borrowings. No borrowings were outstanding under the revolving credit facilities as of June 30, 2024 and December 31, 2023.

RECEIVABLES

RECEIVABLES	6 Months Ended
	Jun. 30, 2024
Accounts Receivable, after Allowance for Credit Loss [Abstract]
RECEIVABLES	RECEIVABLES Dollars in millions June 30, December 31, Trade receivables $ 10,471 $ 9,551 Less: charge-backs and cash discounts (686) (646) Less: allowance for expected credit loss (39) (23) Net trade receivables 9,746 8,882 Alliance, royalties, VAT and other 1,677 2,039 Receivables $ 11,423 $ 10,921 Non-U.S. receivables sold on a nonrecourse basis were $304 million and $503 million for the six months ended June 30, 2024 and 2023, respectively. Receivables from the three largest customers in the U.S. represented 74% and 72% of total trade receivables as of June 30, 2024 and December 31, 2023, respectively.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2024
Inventory, Net [Abstract]
INVENTORIES	INVENTORIES Dollars in millions June 30, December 31, Finished goods $ 862 $ 663 Work in process 2,807 2,430 Raw and packaging materials 437 475 Total inventories $ 4,106 $ 3,568 Inventories $ 3,077 $ 2,662 Other non-current assets 1,029 906

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Dollars in millions June 30, December 31, Land $ 162 $ 162 Buildings 6,670 6,495 Machinery, equipment and fixtures 3,845 3,717 Construction in progress 1,255 1,075 Gross property, plant and equipment 11,932 11,449 Less accumulated depreciation (5,087) (4,803) Property, plant and equipment $ 6,845 $ 6,646 Depreciation expense was $161 million and $316 million for the three and six months ended June 30, 2024 and $151 million and $297 million for the three and six months ended June 30, 2023, respectively.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill The changes in the carrying amounts in Goodwill were as follows: Dollars in millions Balance at December 31, 2023 $ 21,169 Acquisitions (Note 4) 580 Currency translation and other adjustments (17) Balance at June 30, 2024 $ 21,732 Other Intangible Assets Other intangible assets consisted of the following: Estimated June 30, 2024 December 31, 2023 Dollars in millions Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net R&D technology (a) 6 years $ 1,980 $ (110) $ 1,870 $ — $ — $ — Acquired marketed product rights (a) 3 – 15 years 63,473 (44,726) 18,747 63,076 (40,184) 22,892 Capitalized software 3 – 10 years 1,532 (1,096) 436 1,497 (1,027) 470 IPRD (a) 8,375 — 8,375 3,710 — 3,710 Total $ 75,360 $ (45,932) $ 29,428 $ 68,283 $ (41,211) $ 27,072 (a) Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements." Amortization expense of Other intangible assets was $2.4 billion and $4.8 billion during the three and six months ended June 30, 2024 and $2.3 billion and $4.6 billion during the three and six months ended June 30, 2023, respectively. During the three months ended June 30, 2024, a $280 million impairment charge was recorded in Cost of products sold resulting from lower revised cash flow projections for Inrebic . The charge represented a partial impairment based on the excess of the asset’s carrying value over its estimated fair value using discounted cash flow projections. Additionally, a $590 million IPRD impairment charge for alnuctamab was recorded in Research and development expense in connection with portfolio prioritization. Alnuctamab was being studied as a potential treatment for hematologic diseases and was obtained in the acquisition of Celgene. The charge represented a full write-down of the asset.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2024
Supplemental Financial Information [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	SUPPLEMENTAL FINANCIAL INFORMATION Dollars in millions June 30, December 31, 2023 Income taxes $ 3,337 $ 3,927 Research and development 799 723 Contract assets 386 416 Restricted cash (a) 2 55 Other 1,213 786 Other current assets $ 5,737 $ 5,907 Dollars in millions June 30, December 31, 2023 Equity investments (Note 9) $ 2,000 $ 1,699 Operating leases 1,316 1,390 Inventories (Note 12) 1,029 906 Pension and postretirement 210 284 Research and development 411 413 Restricted cash (a) 1 — Receivables and convertible notes 642 436 Other 462 242 Other non-current assets $ 6,071 $ 5,370 (a) Cash is restricted when withdrawal or general use is contractually or legally restricted. As of June 30, 2023, restricted cash of $53 million was included in Cash, cash equivalents and restricted cash in the consolidated statement of cash flows. Dollars in millions June 30, December 31, 2023 Rebates and discounts $ 7,686 $ 7,680 Income taxes 1,474 1,371 Employee compensation and benefits 921 1,291 Research and development 1,231 1,257 Dividends 1,217 1,213 Interest 591 349 Royalties 422 465 Operating leases 177 162 Other 2,264 2,096 Other current liabilities $ 15,983 $ 15,884 Dollars in millions June 30, December 31, 2023 Income taxes $ 1,783 $ 3,288 Pension and postretirement 466 480 Operating leases 1,438 1,530 Deferred income 263 300 Deferred compensation 467 427 Contingent value rights 248 — Other 328 396 Other non-current liabilities $ 4,993 $ 6,421

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
EQUITY	EQUITY The following table summarizes changes in equity during the six months ended June 30, 2024: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and shares in millions Shares Par Value Shares Cost Balance at December 31, 2023 2,923 $ 292 $ 45,684 $ (1,546) $ 28,766 902 $ (43,766) $ 55 Net (loss)/earnings — — — — (11,911) — — 3 Other comprehensive income/(loss) — — — 146 — — — — Cash dividends declared $0.60 per share — — — — (1,215) — — — Stock compensation — — (29) — — (6) 69 — Balance at March 31, 2024 2,923 $ 292 $ 45,655 $ (1,400) $ 15,640 896 $ (43,697) $ 58 Net earnings — — — — 1,680 — — 4 Other comprehensive loss — — — (56) — — — — Cash dividends declared $0.60 per share — — — — (1,217) — — — Stock compensation — — 111 — — — 7 — Distributions — — — — — — — (8) Balance at June 30, 2024 2,923 $ 292 $ 45,766 $ (1,456) $ 16,103 896 $ (43,690) $ 54 The following table summarizes changes in equity during the six months ended June 30, 2023: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and shares in millions Shares Par Value Shares Cost Balance at December 31, 2022 2,923 $ 292 $ 45,165 $ (1,281) $ 25,503 825 $ (38,618) $ 57 Net earnings — — — — 2,262 — — 5 Other comprehensive income/(loss) — — — (87) — — — — Cash dividends declared $0.57 per share — — — — (1,197) — — — Share repurchase program — — — — — 4 (250) — Stock compensation — — (25) — — (6) 60 — Balance at March 31, 2023 2,923 $ 292 $ 45,140 $ (1,368) $ 26,568 823 $ (38,808) $ 62 Net earnings — — — — 2,073 — — 4 Other comprehensive income — — — (19) — — — — Cash dividends declared $0.57 per share — — — — (1,192) — — — Stock repurchase program — — — — — 13 (911) — Stock compensation — — 159 — — (2) 39 — Distributions — — — — — — — (9) Balance at June 30, 2023 2,923 292 45,299 (1,387) 27,449 834 (39,680) 57 The following table summarizes the changes in Other comprehensive income by component: Three Months Ended June 30, 2024 Six Months Ended June 30, 2024 Dollars in millions Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges Recognized in Other comprehensive income/(loss) $ 84 $ (12) $ 72 $ 338 $ (59) $ 279 Reclassified to net earnings (a) (20) 2 (18) (35) 1 (34) Derivatives qualifying as cash flow hedges 64 (10) 54 303 (58) 245 Pension and postretirement benefits Actuarial gains/(losses) (87) 21 (66) (93) 22 (71) Amortization (b) 1 — 1 3 — 3 Settlements (b) — 1 1 19 (2) 17 Pension and postretirement benefits (86) 22 (64) (71) 20 (51) Unrealized losses on marketable debt securities (1) 1 — (3) 1 (2) Foreign currency translation (37) (9) (46) (81) (21) (102) Other comprehensive income/(loss) $ (60) $ 4 $ (56) $ 148 $ (58) $ 90 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Dollars in millions Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges Recognized in Other comprehensive income/(loss) $ 94 $ (16) $ 78 $ 81 $ (13) $ 68 Reclassified to net earnings (a) (86) 11 (75) (219) 30 (189) Derivatives qualifying as cash flow hedges 8 (5) 3 (138) 17 (121) Pension and postretirement benefits Actuarial gains/(losses) (13) 2 (11) (13) 2 (11) Foreign currency translation (4) (7) (11) 31 (5) 26 Other comprehensive income/(loss) $ (9) $ (10) $ (19) $ (120) $ 14 $ (106) (a) Included in Cost of products sold and Other (income)/expense, net. Refer to "—Note 9. Financial Instruments and Fair Value Measurements" for further information. (b) Included in Other (income)/expense, net. The accumulated balances related to each component of Other comprehensive (loss)/income, net of taxes, were as follows: Dollars in millions June 30, December 31, Derivatives qualifying as cash flow hedges $ 247 $ 2 Pension and postretirement benefits (789) (738) Marketable debt securities — 2 Foreign currency translation (a) (914) (812) Accumulated other comprehensive loss $ (1,456) $ (1,546) (a) Includes net investment hedge gains of $215 million and $144 million as of June 30, 2024 and December 31, 2023, respectively.

EMPLOYEE STOCK BENEFIT PLANS

EMPLOYEE STOCK BENEFIT PLANS	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
EMPLOYEE STOCK BENEFIT PLANS	EMPLOYEE STOCK BENEFIT PLANS Stock-based compensation expense was as follows: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Cost of products sold $ 14 $ 13 $ 28 $ 24 Marketing, selling and administrative 48 56 101 107 Research and development 63 68 129 128 Total Stock-based compensation expense $ 125 $ 137 $ 258 $ 259 Income tax benefit (a) $ 27 $ 27 $ 55 $ 52 (a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $(3) million and $(20) million for the three and six months ended June 30, 2024, and $2 million and $20 million for the three and six months ended June 30, 2023, respectively. The number of units granted and the weighted-average fair value on the grant date for the six months ended June 30, 2024 were as follows: Units in millions Units Weighted-Average Fair Value Restricted stock units 13.0 $ 47.54 Market share units 1.3 $ 58.63 Performance share units 1.9 $ 53.08 Dollars in millions Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 1,075 $ 90 $ 123 Expected weighted-average period in years of compensation cost to be recognized 2.9 2.6 2.1

LEGAL PROCEEDINGS AND CONTINGEN

LEGAL PROCEEDINGS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS AND CONTINGENCIES	LEGAL PROCEEDINGS AND CONTINGENCIES BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below. While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial claims and/or defenses in the matters, the outcomes of BMS's legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS's financial position, results of operations or cash flows for a particular period. Furthermore, failure to successfully enforce BMS's patent rights would likely result in substantial decreases in the respective product revenues from generic competition. Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see " —Note 7. Income Taxes." INTELLECTUAL PROPERTY Eliquis - Europe Lawsuits have been filed by generic companies in various countries in Europe seeking revocation of our composition-of-matter patents and SPCs relating to Eliquis, and trials or preliminary proceedings have been held in certain of those cases. In Belgium, BMS filed infringement proceedings against Sandoz in February 2024. A hearing date in these proceedings has been scheduled for November 2024. In Croatia, in February 2024, the court granted BMS's request for a preliminary injunction to prohibit Teva from offering, storing or selling generic Eliquis products in Croatia. Teva has appealed this decision. In Finland, the court granted our request for a preliminary injunction prohibiting Teva from offering, storing or selling generic Eliquis products in Finland that have obtained price and reimbursement. A trial regarding Teva's challenge to the validity of the Finnish composition-of-matter patent and related SPC concluded on July 5, 2023. On May 22, 2024, the Finnish court held the patent to be invalid. BMS will seek permission to appeal this decision. In France, a trial was held regarding Teva's challenge to the validity of the French composition-of-matter patent and related SPC, and a decision was issued on June 8, 2023, confirming their validity and rejecting Teva's claims. Teva has appealed the decision and a hearing of the appeal has been scheduled for April 2025. In Ireland, the court granted our request for a preliminary injunction prohibiting Teva from making, offering, putting on the market and/or using and/or importing or stocking for the aforesaid purposes, generic Eliquis products. The trial court's preliminary injunction decision was subsequently affirmed on appeal by the Irish Court of Appeal. In a decision delivered on December 8, 2023, the Irish trial court found the Irish composition-of-matter patent and related SPC to be invalid. BMS appealed the Irish trial court's decision. On June 13, 2024, the Irish Court of Appeal entered an injunction restraining Teva from launching its generic product pending the determination of BMS's appeal of the trial court's invalidity decision. In the Netherlands, our requests for preliminary injunctions to prevent at-risk generic launches by Sandoz, Stada and Teva prior to full trials on the validity of the Dutch composition-of-matter patent and SPC were initially denied by the lower courts. However, in a judgment issued on August 15, 2023, the Dutch Court of Appeal overturned the decisions of the lower court, issued preliminary injunctions against Sandoz, Stada and Teva and ordered those companies to recall any generic Eliquis product from the Dutch market. Trials regarding challenges brought by Sandoz and Teva, respectively, to the validity of the Dutch composition-of-matter patent and related SPC took place on October 13, 2023 and January 12, 2024, and decisions are pending. In Norway, a trial was held regarding Teva's challenge to the validity of the Norwegian composition-of-matter patent and related SPC, and a decision was issued on May 23, 2023, confirming their validity and rejecting Teva's claims. Teva appealed the decision, and on June 3, 2024, the Court of Appeal issued a decision confirming the validity of the patent and related SPC. The deadline for Teva to appeal the decision of the Court of Appeal is August 19, 2024. In Portugal, there are patent validity and infringement proceedings pending with multiple companies seeking to market generic versions of Eliquis . A trial regarding Mylan's challenge to the validity of the Portuguese composition-of-matter patent began in February 2024 and is ongoing. In early September 2023, Teva launched a generic Eliquis product on the Portuguese market. On September 15, 2023, the Company filed a request for a preliminary injunction against Teva at the Portuguese Intellectual Property Court. The hearing of the preliminary injunction against Teva is ongoing. In Romania, our request for a preliminary injunction against Teva was initially denied by the lower court. However, in January 2024, the Romania Court of Appeal overturned the decision of the lower court, and issued a preliminary injunction against Teva prohibiting Teva from offering, storing or selling generic Eliquis products in Romania. In Spain, a trial regarding Teva's challenge to the validity of the Spanish composition-of-matter patent and related SPC was held on October 18-19, 2023, and in a decision delivered in January 2024, the Barcelona Commercial Court found the Spanish composition-of-matter patent and related SPC to be invalid. BMS appealed the decision of the Barcelona Commercial Court to the Barcelona Court of Appeal. In February 2024, the Madrid Commercial Court granted BMS’s preliminary injunctions against Teva, Sandoz and Normon pending determination of the appeal of the decision of the Barcelona Commercial Court. Teva sought an order from the Barcelona Commercial Court to effectively overturn the preliminary injunction. BMS then sought and was granted an order from the Madrid Commercial Court requiring Teva to comply with the preliminary injunction. The issue was referred to the Spanish Supreme Court, which on April 26, 2024 issued a judgment requiring the Madrid Commercial Court to lift the injunction in place against Teva. On July 16, 2024, the Madrid Commercial Court issued a decision maintaining the preliminary injunctions against Sandoz and Normon. In a decision dated July 18, 2024, the Barcelona Court of Appeal overturned the decision of the Barcelona Commercial Court and upheld the validity of the Spanish composition-of-matter patent and related SPC. In Sweden, a trial was held regarding Teva's challenge to the validity of the Swedish composition-of-matter patent and related SPC, and a decision was issued on November 2, 2022, confirming their validity and rejecting Teva's claims. Teva appealed the decision, and the appeal was heard in May 2024. On June 20, 2024, the Court of Appeal issued a decision upholding the validity of the patent and related SPC. In Switzerland, a trial was held regarding Teva's challenge to the validity of the Swiss composition-of-matter patent and related SPC, and a decision was issued on March 8, 2024, confirming their validity and rejecting Teva's claims. Teva has appealed this decision. In the UK, Sandoz and Teva filed lawsuits seeking revocation of the UK composition-of-matter patent and related SPC. BMS subsequently filed counterclaims for infringement in both actions. A combined trial took place in February 2022, and in a judgment issued on April 7, 2022, the judge found the UK apixaban composition-of-matter patent and related SPC invalid. BMS appealed the judgment and on May 4, 2023, the Court of Appeal upheld the lower court's decision. On October 31, 2023, the UK Supreme Court rejected BMS's application to appeal. Following the first instance decision in the UK, generic manufacturers have begun marketing generic versions of Eliquis in the UK. In addition to the above, challenges to the validity of the composition-of-matter patent and related SPC are pending in Denmark, Italy, Poland, Czechia, Slovakia, Hungary, Bulgaria, Greece and Lithuania. Generic manufacturers may seek to market generic versions of Eliquis in additional countries in Europe prior to the expiration of our patents, which may lead to additional infringement and invalidity actions involving Eliquis patents being filed in various countries in Europe. Onureg – U.S. BMS received Notice Letters from Accord Healthcare, Inc. ("Accord"), MSN Laboratories Private Limited ("MSN"), Teva Pharmaceuticals, Inc. ("Teva") and Natco Pharma Limited ("Natco"), respectively, each notifying BMS that it has filed an ANDA containing a paragraph IV certification seeking approval of a generic version of Onureg in the U.S. and challenging U.S. Patent Nos. 11,571,436 (the "'436 Patent") and 8,846,628 (the "'628 Patent"), FDA Orange Book-listed formulation patents covering Onureg , which expire in 2029 and 2030, respectively. In response, BMS filed a patent infringement action against Accord, MSN, Teva and Natco in the U.S. District Court for the District of Delaware. BMS subsequently entered into confidential settlement agreements with each of Accord, MSN, Teva and Natco, and the cases against each have been dismissed. Plavix* - Australia Sanofi was notified that, in August 2007, GenRx Proprietary Limited ("GenRx") obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex ("GenRx-Apotex"). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ("Full Court") appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($298 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages. In May 2020, the Australian government appealed the Federal Court's decision and an appeal hearing concluded in February 2021. On June 26, 2023, the appeal court issued a ruling in BMS and Sanofi's favor, upholding the lower court's decision. In December 2023, the Australian government was granted leave to appeal the decision to the High Court of Australia, and the High Court scheduled an appeal hearing for September 4-6, 2024. Zeposia - U.S. On October 15, 2021, Actelion Pharmaceuticals LTD and Actelion Pharmaceuticals US, INC ("Actelion") filed a complaint for patent infringement in the United States District Court for the District of New Jersey against BMS and Celgene for alleged infringement of U.S. Patent No. 10,251,867 (the "'867 Patent"). The Complaint alleges that the sale of Zeposia infringes certain claims of the '867 Patent and Actelion is seeking damages. No trial date has been scheduled. In May and June 2024, BMS received Notice Letters from Synthon BV ("Synthon") and Apotex Inc. ("Apotex"), respectively, each notifying BMS that it has filed an ANDA containing a paragraph IV certification seeking approval of a generic version of Zeposia in the U.S. and challenging a U.S. patent listed in the Orange Book for Zeposia. In response, BMS filed patent infringement actions against Synthon and Apotex in the U.S. District Court for the District of Delaware. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits BMS and certain Sanofi entities are defendants in a consumer protection action brought by the attorney general of Hawaii relating to the labeling, sales and/or promotion of Plavix *. In February 2021, a Hawaii state court judge issued a decision against Sanofi and BMS, imposing penalties in the total amount of $834 million, with $417 million attributed to BMS. Sanofi and BMS appealed the decision. On March 15, 2023, the Hawaii Supreme Court issued its decision, reversing in part and affirming in part the trial court decision, vacating the penalty award and remanding the case for a new trial and penalty determination. A new bench trial concluded on October 16, 2023. On May 21, 2024, the trial court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $916 million, with $458 million attributed to BMS. Sanofi and BMS will appeal the decision. PRODUCT LIABILITY LITIGATION BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products. Abilify* BMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. Cases were filed in state and federal courts in the United States. Pursuant to a previously disclosed master settlement agreement and settlement related court orders, the vast majority of the cases in the United States were resolved or dismissed. Eleven inactive cases remain pending in state courts in New Jersey. There are also eleven cases pending in Canada (four class actions and seven individual injury claims), two of which are active (the certified class actions in Quebec and Ontario). Onglyza* BMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . In February 2018, the Judicial Panel on Multidistrict Litigation ordered all the federal Onglyza* cases to be transferred to an MDL in the U.S. District Court for the Eastern District of Kentucky. A significant majority of the claims were pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco ("JCCP"). The JCCP court granted summary judgment to defendants in March 2022, a decision which was affirmed by the California Court of Appeal. The California Supreme Court declined to review the decision in July 2023. In the MDL, the court granted defendants' motion to exclude plaintiffs' only general causation expert on January 5, 2022 and granted summary judgment on August 2, 2022. The United States Court of Appeals for the Sixth Circuit affirmed the decision on February 13, 2024 and the deadline to file a petition for certiorari with the Supreme Court of the United States has passed. A small number of plaintiffs in other jurisdictions voluntarily dismissed their claims, and related tolling agreements have expired. As part of BMS's global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca. SECURITIES LITIGATION Celgene Securities Litigations Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the "Celgene Securities Class Action"). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene's 2020 outlook and projected sales of Otezla* , and (3) the NDA for Zeposia . The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiffs' amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. In November 2020, the Court granted class certification with respect to the remaining claims. In March 2023, the Court granted the defendants leave to file a motion for summary judgment, the briefing for which was completed in June 2023. On September 8, 2023, the Court granted in part and denied in part defendants' motion for summary judgment as to the claims regarding statements made by the remaining officer defendants. As to the claims regarding Celgene’s corporate statements, the Court denied the defendants’ motion without prejudice and granted the defendants leave to re-raise the issue. On October 27, 2023, the defendants filed a motion for partial summary judgment as to Celgene’s corporate statements. On July 23, 2024, the Court granted the defendants’ motion as to individual liability for those corporate statements but reserved decision as to the company's liability, noting that another opinion would be forthcoming. In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action (the "Schwab Action"). In July 2020, the defendants filed a motion to dismiss the plaintiffs' complaint in full. In March 2021, the Court granted in part and denied in part defendants' motion to dismiss consistent with its decision in the Celgene Securities Class Action. The California Public Employees' Retirement System in April 2021 (the "CalPERS Action"); DFA Investment Dimensions Group Inc., on behalf of certain of its funds; and American Century Mutual Funds, Inc., on behalf of certain of its funds, in July 2021 (respectively, the "DFA Action" and the "American Century Action"), and GIC Private Limited in September 2021 (the "GIC Action"), filed separate individual actions in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action and the Schwab individual action against the same remaining defendants in those actions. In October 2021, these actions were consolidated for pre-trial proceedings with the Schwab Action. The Court also consolidated any future direct actions raising common questions of law and fact with the Schwab Action (the "Consolidated Schwab Action"). On October 2, 2023, defendants filed a motion for partial summary judgment in the Consolidated Schwab Action. The motion is fully briefed and currently pending before the Court. No trial dates have been scheduled in any of the above Celgene Securities Litigations. Contingent Value Rights Litigations In June 2021, an action was filed against BMS in the U.S. District Court for the Southern District of New York asserting claims of alleged breaches of a Contingent Value Rights Agreement ("CVR Agreement") entered into in connection with the closing of BMS's acquisition of Celgene in November 2019. An entity claiming to be the successor trustee under the CVR Agreement alleges that BMS breached the CVR Agreement by allegedly failing to use "diligent efforts" to obtain FDA approval of liso-cel ( Breyanzi ) before a contractual milestone date, thereby allegedly avoiding a $6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the alleged successor trustee. The plaintiff seeks damages in an amount to be determined at trial and other relief, including interest and attorneys' fees. BMS disputes the allegations. BMS filed a motion to dismiss the alleged successor trustee's complaint for failure to state a claim upon which relief can be granted, which was denied on June 24, 2022. On February 2, 2024, BMS filed a motion to dismiss the complaint for lack of subject matter jurisdiction. In October 2021, alleged former Celgene stockholders filed a complaint in the U.S. District Court for the Southern District of New York asserting claims on behalf of a putative class of Celgene stockholders who received CVRs in the BMS merger with Celgene for violations of sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") relating to the joint proxy statement. That action later was consolidated with another action filed in the same court, and a consolidated complaint thereafter was filed asserting claims on behalf of a class of CVR acquirers, whether in the BMS merger with Celgene or otherwise, for violations of sections 11, 12(a)(2), and 15 of the Securities Act of 1933 (the "Securities Act") and sections 10(b), 14(a) and 20(2) of the Exchange Act. The complaint alleged that the February 22, 2019 joint proxy statement was materially false or misleading because it failed to disclose that BMS allegedly had no intention to obtain FDA approval for liso-cel ( Breyanzi ) by the applicable milestone date in the CVR Agreement and that certain statements made by BMS or certain BMS officers in periodic SEC filings, earnings calls, press releases, and investor presentations between December 2019 and November 2020 were materially false or misleading for the same reason. Defendants moved to dismiss the complaint. On March 1, 2023, the Court entered an opinion and order granting defendants' motion and dismissed the complaint in its entirety. The claims under Sections 11, 12(a)(2), and 15 of the Securities Act and Section 14(a) of the Exchange Act were dismissed with prejudice. The claims under Sections 10(a) and 20(a) of the Exchange Act were dismissed with leave to file a further amended complaint, which plaintiffs filed on April 14, 2023. Defendants moved to dismiss the amended complaint and briefing on the motion was completed on June 23, 2023. In an opinion and order entered on February 29, 2024, the Court granted that motion in its entirety and dismissed the remaining claims with prejudice. On March 28, 2024, plaintiffs filed a notice of appeal. In November 2021, an alleged purchaser of CVRs filed a complaint in the Supreme Court of the State of New York for New York County asserting claims on behalf of a putative class of CVR acquirers for violations of sections 11(a) and 12(a)(2) of the Securities Act of 1933. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel ( Breyanzi ) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, and certain BMS officers who signed the registration statement. Defendants moved to stay the action pending resolution of the federal action or, in the alternative, to dismiss the complaint and later filed a similar motion in response to an amended complaint. On February 2, 2024, the Court granted defendants’ motion and dismissed the case in its entirety. On February 29, 2024, the plaintiff filed a notice of appeal. In November 2021, an alleged Celgene stockholder filed a complaint in the Superior Court of New Jersey, Union County asserting claims on behalf of two separate putative classes, one of acquirers of CVRs and one of acquirers of BMS common stock, for violations of sections 11(a), 12(a)(2), and 15 of the Securities Act. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel ( Breyanzi ) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, certain BMS officers who signed the registration statement and Celgene's former chairman and chief executive officer. The Court had temporarily stayed the action pending resolution of the federal action, but lifted the stay on March 21, 2024, following the dismissal of the federal action. On April 4, 2024, defendants moved to dismiss the New Jersey complaint. On June 25, 2024, the Court granted defendants' motion and dismissed the complaint in its entirety without prejudice. No trial dates have been scheduled in any of the above CVR Litigations. OTHER LITIGATION IRA Litigation On June 16, 2023, BMS filed a lawsuit against the U.S. Department of Health & Human Services and the Centers for Medicare & Medicaid Services, et al. , challenging the constitutionality of the drug-pricing program in the IRA. That program requires pharmaceutical companies, like BMS, under the threat of significant penalties, to sell certain of their medicines at government-dictated prices. On August 29, 2023, the government selected Eliquis for this program. In its lawsuit, BMS argues that this program violates the Fifth Amendment, which requires the government to pay just compensation if it takes property for public use, by requiring pharmaceutical manufacturers to provide medicines to third parties at prices set by the government that necessarily fall below fair market value. BMS also argues that this program violates the First Amendment right to free speech by requiring manufacturers to state that they agree that the price set by the government is the medicine's "maximum fair price" as determined by negotiation, even though there is no true negotiation. On August 16, 2023, BMS filed a motion for summary judgment. On October 16, 2023, the government filed an opposition to BMS’s motion for summary judgment and a cross-motion for summary judgment. The court heard oral argument on the parties' summary judgment motions on March 7, 2024. On April 29, 2024, the court issued an opinion and order that denied BMS's motion for summary judgment and granted the government's cross-motion for summary judgment. BMS appealed to the United States Court of Appeals for the Third Circuit and briefing on the appeal is scheduled to be completed by October 2, 2024. Thalomid and Revlimid Litigations Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for ANDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid , and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, sought injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In March 2020, Celgene reached a settlement with the class plaintiffs. In October 2020, the Court entered a final order approving the settlement and dismissed the matter. That settlement did not resolve certain claims of certain entities that opted out of the settlement, and who have since filed new suits advancing related theories. As described below, certain other consolidated or coordinated suits are pending. In March 2019, Humana Inc. ("Humana"), which opted out of the above settlement, filed a lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana's complaint makes largely the same claims and allegations as were made in the now settled Thalomid and Revlimid antitrust class action litigation. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys' fees and costs. In May 2019, Celgene filed a motion to dismiss Humana's complaint. In April 2022, the Court issued an order denying Celgene's motion to dismiss. That order addressed only Celgene's argument that certain of Humana's claims were barred by the statute of limitations. The Court's order did not address Celgene's other grounds for dismissal and instead directed Celgene to present those arguments in a renewed motion to dismiss following the filing of amended complaints. In May 2022, Humana filed an amended complaint against Celgene and BMS asserting the same claims based on additional factual allegations. Celgene and BMS subsequently filed a motion to dismiss Humana's amended complaint. On August 18, and September 8, 2023, the Court held argument on Celgene and BMS' motion. On June 6, 2024, the Court granted Celgene and BMS's motion to dismiss in its entirety. The Court granted Humana and the other plaintiffs referenced immediately below (

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,680	$ 2,073	$ (10,231)	$ 4,335

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION AND REC_2

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation Bristol-Myers Squibb Company ("BMS", "we", "our", "us" or "the Company") prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position of the Company as of June 30, 2024 and December 31, 2023 and the results of operations for the three and six months ended June 30, 2024 and 2023, and cash flows for the six months ended June 30, 2024 and 2023. All intercompany balances and transactions have been eliminated. These consolidated financial statements and the related footnotes should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2023 included in the 2023 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
Business Segment Information	Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS's operational structure, the Chief Executive Officer ("CEO"), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see "—Note 2. Revenue".
Use of Estimates and Judgements	Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of intangible assets; charge-backs, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates.
Recently Adopted Accounting Standards	Recently Issued Accounting Standards Not Yet Adopted Income Taxes In December 2023, the FASB issued amended guidance on income tax disclosures. The guidance is intended to provide additional disaggregation to the effective income tax rate reconciliation and income tax payment disclosures. The amended guidance is effective for annual periods beginning January 1, 2025 and should be applied on a prospective basis. Early adoption is permitted. Segment Reporting In November 2023, the FASB issued amended guidance for improvements to reportable segment disclosures. The revised guidance requires that a public entity disclose significant segment expenses regularly reviewed by the chief operating decision maker (CODM), including public entities with a single reportable segment. The amended guidance is effective for fiscal years beginning January 1, 2024 and interim periods beginning January 1, 2025 and should be applied on a retrospective basis. Early adoption is permitted.

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes the disaggregation of revenue by nature: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Net product sales $ 11,925 $ 10,917 $ 23,484 $ 21,965 Alliance revenues 116 179 250 323 Other revenues 160 130 332 275 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563
Revenue Recognition Gross-To-Net Adjustments	The following table summarizes GTN adjustments: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Gross product sales $ 20,780 $ 18,111 $ 40,075 $ 35,399 GTN adjustments (a) Charge-backs and cash discounts (2,843) (2,279) (5,399) (4,370) Medicaid and Medicare rebates (3,864) (3,143) (6,948) (5,625) Other rebates, returns, discounts and adjustments (2,148) (1,772) (4,244) (3,439) Total GTN adjustments (b) (8,855) (7,194) (16,591) (13,434) Net product sales $ 11,925 $ 10,917 $ 23,484 $ 21,965 (a) Includes reductions/(increases) to GTN adjustments for product sales made in prior periods resulting from changes in estimates of ($19 million) and $61 million for the three and six months ended June 30, 2024 and $11 million and $98 million for the three and six months ended June 30, 2023, respectively. (b) Includes U.S. GTN adjustments of $8.0 billion and $14.9 billion for the three and six months ended June 30, 2024 and $6.4 billion and $11.9 billion for the three and six months ended June 30, 2023, respectively.
Revenue from External Customers by Products and Services	The following table summarizes the disaggregation of revenue by product and region: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Growth Portfolio Opdivo $ 2,387 $ 2,145 4,465 $ 4,347 Orencia 948 927 1,746 1,691 Yervoy 630 585 1,213 1,093 Reblozyl 425 234 779 440 Opdualag 235 154 441 271 Abecma 95 132 177 279 Zeposia 151 100 261 178 Breyanzi 153 100 260 171 Camzyos 139 46 223 75 Sotyktu 53 25 97 41 Augtyro 7 — 13 — Krazati 32 — 53 — Other Growth products (a) 341 295 660 575 Total Growth Portfolio 5,596 4,743 10,388 9,161 Legacy Portfolio Eliquis 3,416 3,204 7,136 6,627 Revlimid 1,353 1,468 3,022 3,218 Pomalyst/Imnovid 959 847 1,824 1,679 Sprycel 424 458 798 887 Abraxane 231 258 448 497 Other Legacy products (b) 222 248 450 494 Total Legacy Portfolio 6,605 6,483 13,678 13,402 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563 United States $ 8,801 $ 7,804 $ 17,277 $ 15,756 International 3,224 3,247 6,414 6,477 Other (c) 176 175 375 330 Total Revenues $ 12,201 $ 11,226 $ 24,066 $ 22,563 (a) Includes Onureg , Inrebic , Nulojix , Empliciti and royalty revenues. (b) Includes other mature brands. (c) Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.

ALLIANCES (Tables)

ALLIANCES (Tables)	6 Months Ended
	Jun. 30, 2024
ALLIANCES [Abstract]
Selected Financial Information For Alliances	Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Revenues from alliances Net product sales $ 3,470 $ 3,320 $ 7,232 $ 6,852 Alliance revenues 116 179 250 323 Total alliance revenues $ 3,586 $ 3,499 $ 7,482 $ 7,175 To/(from) alliance partners Cost of products sold $ 1,692 $ 1,614 $ 3,517 $ 3,320 Marketing, selling and administrative (65) (64) (144) (138) Research and development 46 36 100 80 Acquired IPRD 80 55 880 55 Other (income)/expense, net (102) (15) (114) (27) Dollars in millions June 30, December 31, Selected alliance balance sheet information Receivables – from alliance partners $ 290 $ 233 Accounts payable – to alliance partners 1,627 1,394 Deferred income – from alliances (a) 248 274 (a)

ACQUISITIONS, DIVESTITURES, L_2

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)	6 Months Ended
	Jun. 30, 2024
Acquisitions, Divestitures and Other Arrangements [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following summarizes the total consideration transferred and allocation of consideration transferred to the assets acquired, liabilities assumed and Acquired IPRD expense: Dollars in millions Cash consideration for outstanding shares $ 12,606 Cash consideration for equity awards 1,421 Consideration to be paid 14,027 Less: Charge for unvested stock awards (a) (289) Transaction costs 55 Total consideration allocated $ 13,793 Cash and cash equivalents $ 1,167 Other assets 67 Intangible assets 100 Deferred income tax asset 542 Deferred income tax liability (25) Other liabilities (180) Total identifiable assets acquired, net 1,671 Acquired IPRD expense 12,122 Total consideration allocated $ 13,793 (a) Includes cash-settled unvested equity awards of $130 million expensed in Marketing, selling and administrative and $159 million expensed in Research and development during the six months ended June 30, 2024. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed as of the acquisition date based upon their respective preliminary fair values summarized below: Dollars in millions Preliminary Purchase Price Allocation Cash and cash equivalents $ 501 Other assets 70 Intangible assets 3,700 Deferred income tax asset 81 Deferred income tax liability (798) Other liabilities (109) Identifiable net assets acquired $ 3,445 Goodwill 428 Total consideration allocated $ 3,873 The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed as of the acquisition date based upon their respective preliminary fair values summarized below: Dollars in millions Preliminary purchase price allocation Cash and cash equivalents $ 748 Inventories 215 Other assets 159 Intangible assets 4,225 Deferred income tax assets 734 Deferred income tax liabilities (1,094) Other liabilities (204) Identifiable net assets acquired $ 4,783 Goodwill 152 Total consideration allocated $ 4,935
Schedule of Business Acquisitions, by Acquisition	Total consideration for the acquisition consisted of the following: Dollars in millions Cash consideration for outstanding shares $ 3,851 Cash consideration for equity awards 296 Consideration paid 4,147 Less: Unvested stock awards (a) (274) Total consideration allocated $ 3,873 (a) Includes cash settlement for unvested equity awards of $159 million expensed in Marketing, selling and administrative and $115 million expensed in Research and development during the six months ended June 30, 2024. Total consideration for the acquisition consisted of the following: Dollars in millions Cash consideration for outstanding shares $ 4,596 Cash consideration for equity awards 205 Consideration paid 4,801 Plus: Fair value of CVRs 248 Less: unvested stock awards (a) (114) Total consideration allocated $ 4,935 (a) Includes cash settlement of unvested equity awards of $60 million expensed in Marketing, selling and administrative and $54 million expensed in Research and development during six months ended June 30, 2024.
Divestitures	The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses). Three Months Ended June 30, Net Proceeds Divestiture (Gains)/Losses Royalty Income Dollars in millions 2024 2023 2024 2023 2024 2023 Diabetes business - royalties $ 265 $ 185 $ — $ — $ (265) $ (218) Mature products and other — 3 — — — — Total $ 265 $ 188 — $ — $ (265) (218) Six Months Ended June 30, Net Proceeds Divestiture (Gains)/Losses Royalty Income Dollars in millions 2024 2023 2024 2023 2024 2023 Diabetes business - royalties $ 496 $ 401 $ — $ — $ (536) $ (406) Mature products and other — 7 — — — — Total $ 496 $ 408 — $ — $ (536) (406)
Licensing and Other Arrangements	The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Keytruda * royalties $ (137) $ (284) $ (270) $ (563) Tecentriq * royalties (11) (24) (23) (54) Contingent milestone income (25) (5) (25) (36) Amortization of deferred income (12) (15) (24) (27) Other royalties and licensing income (6) (12) (10) (23) Royalty and licensing income $ (191) $ (340) $ (352) $ (703)

OTHER (INCOME)_EXPENSE, NET (Ta

OTHER (INCOME)/EXPENSE, NET (Tables)	6 Months Ended
	Jun. 30, 2024
Other Nonoperating Income (Expense) [Abstract]
Schedule Of Other Income Expense	Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Interest expense (Note 10) $ 521 $ 282 $ 946 $ 570 Royalty and licensing income (Note 4) (191) (340) (352) (703) Royalty income - divestiture (Note 4) (265) (218) (536) (406) Investment income (87) (95) (270) (197) Litigation and other settlements (a) 69 (7) 71 (332) Provision for restructuring (Note 6) 260 113 480 180 Integration expenses (Note 6) 74 59 145 126 Equity investment (gain)/losses (Note 9) (107) 58 (209) 213 Acquisition expense (Note 4) 1 — 50 — Other (2) 32 29 20 Other (income)/expense, net $ 273 $ (116) $ 354 $ (529) (a) Includes $90 million of income related to the Eisai collaboration termination incurred during the three months ended June 30, 2024 and $400 million of income related to Nimbus' TYK2 program change of control provision incurred during the six months ended June, 30 2023.

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	6 Months Ended
	Jun. 30, 2024
Restructuring Charges [Abstract]
Restructuring and Related Costs	The following provides the charges related to restructuring initiatives by type of cost: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 2023 Restructuring Plan $ 264 $ 170 $ 332 $ 231 Celgene and Other Acquisition Plans 93 64 337 138 Total charges $ 357 $ 234 $ 669 $ 369 Employee termination costs $ 260 $ 109 $ 477 $ 174 Other termination costs — 4 3 6 Provision for restructuring 260 113 480 180 Integration expenses 74 59 145 126 Accelerated depreciation 20 12 34 13 Asset impairments — 50 2 50 Other shutdown costs 3 — 8 — Total charges $ 357 $ 234 $ 669 $ 369 Cost of products sold $ 3 $ 36 $ 17 $ 37 Marketing, selling and administrative 6 20 12 20 Research and development 14 6 15 6 Other (income)/expense, net 334 172 625 306 Total charges $ 357 $ 234 $ 669 $ 369
Schedule of Restructuring Reserve by Type of Cost	The following summarizes the charges and spending related to restructuring plan activities: Six Months Ended June 30, Dollars in millions 2024 2023 Beginning balance $ 188 $ 47 Provision for restructuring 480 180 Foreign currency translation and other (3) 1 Payments (234) (48) Ending balance $ 431 $ 180

INCOME TAXES (Tables)

INCOME TAXES (Tables)	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Earnings/(Loss) before income taxes $ 1,286 $ 1,859 $ (10,230) $ 4,629 Income tax (benefit)/provision (398) (218) (6) 285 Effective tax rate (30.9) % (11.7) % 0.1 % 6.2 %

EARNINGS_(LOSS) PER SHARE (Tabl

EARNINGS/(LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings/(Loss) Per Share, Basic and Diluted	Three Months Ended June 30, Six Months Ended June 30, Dollars in millions, except per share data 2024 2023 2024 2023 Net earnings/(loss) attributable to BMS $ 1,680 $ 2,073 $ (10,231) $ 4,335 Weighted-average common shares outstanding – basic 2,027 2,093 2,025 2,096 Incremental shares attributable to share-based compensation plans 2 9 — 11 Weighted-average common shares outstanding – diluted 2,029 2,102 2,025 2,107 Earnings/(Loss) per common share Basic $ 0.83 $ 0.99 $ (5.05) $ 2.07 Diluted 0.83 0.99 (5.05) 2.06

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis are summarized below: June 30, 2024 December 31, 2023 Dollars in millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents Money market and other securities $ — $ 4,004 $ — $ — $ 8,489 $ — Marketable debt securities Certificates of deposit — 201 — — 609 — Commercial paper — — — — 92 — Corporate debt securities — 475 — — 460 — U.S. Treasury securities — 41 — — 19 — Derivative assets — 456 — — 219 — Equity investments 494 99 — 318 141 — Derivative liabilities — 114 — — 160 — Contingent consideration liability Contingent value rights (a) 2 — 248 4 — — Other acquisition related contingent consideration — — — — — 8
Schedule of Equity Investments	The following summarizes the carrying amount of equity investments: Dollars in millions June 30, December 31, Equity investments with readily determinable fair values $ 593 $ 459 Equity investments without readily determinable fair values 785 698 Limited partnerships and other equity method investments 622 542 Total equity investments $ 2,000 $ 1,699
Debt Securities, Trading, and Equity Securities, FV-NI	The following summarizes the activity related to equity investments. Changes in fair value of equity investments are included in Other (income)/expense, net. Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Equity investments with RDFV Net (gain)/loss recognized $ (36) $ 47 (122) 188 Less: net (gain)/loss recognized on investments sold — (11) 1 (12) Net unrealized (gain)/loss recognized on investments still held (36) 58 (123) 200 Equity investments without RDFV Upward adjustments (11) — (21) (6) Net realized (gain)/loss recognized on investments sold (36) — (36) — Impairments and downward adjustments 4 — 29 — Equity in net (income)/loss of affiliates (28) 11 (59) 31 Total equity investment (gains)/losses $ (107) $ 58 (209) 213
Schedule of Derivatives and Fair Value	The following table summarizes the fair value and the notional values of outstanding derivatives: June 30, 2024 December 31, 2023 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Designated as cash flow hedges Foreign currency exchange contracts $ 6,115 $ 256 $ 403 $ (8) $ 4,772 $ 130 $ 1,971 $ (66) Cross-currency swap contracts 583 24 627 (8) 1,210 50 — — Designated as net investment hedges Foreign currency exchange contracts 505 36 377 (2) — — 215 (8) Cross-currency swap contracts 396 29 292 (13) — — 747 (43) Designated as fair value hedges Interest rate swap contracts 1,000 1 2,255 (18) 2,500 3 1,755 (14) Not designated as hedges Foreign currency exchange contracts 3,122 103 1,749 (65) 906 20 1,250 (29) Total return swap contracts (c) $ 441 $ 7 $ — $ — $ 401 $ 16 $ — $ — (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities. (c) Total return swap contracts hedge changes in fair value of certain deferred compensation liabilities.
Derivative Instruments, Gain (Loss)	The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedges: Three Months Ended June 30, 2024 Six Months Ended June 30, 2024 Dollars in millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Foreign currency exchange contracts $ (29) $ (40) $ (74) $ (53) Cross-currency swap contracts — 7 — 36 Interest rate swap contracts — 4 — 7 Forward interest rate contracts — (1) — (2) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Dollars in millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Foreign currency exchange contracts $ (90) $ (44) $ (210) $ (60) Cross-currency swap contracts — (5) — (28) Interest rate swap contracts — (4) — (7) The following table summarizes the effect of derivative and non-derivative instruments designated as hedges in Other comprehensive income: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Derivatives designated as cash flow hedges Foreign exchange contracts gain/(loss): Recognized in Other comprehensive (loss)/income $ 102 $ 60 $ 241 $ 53 Reclassified to Cost of products sold (29) (90) (74) (210) Cross-currency swap contracts gain/(loss): Recognized in Other comprehensive (loss)/income (18) 34 (34) 28 Reclassified to Other (income)/expense, net 10 4 41 (9) Forward interest rate contract gain/(loss): Recognized in Other comprehensive (loss)/income — — 131 — Reclassified to Other (income)/expense, net (1) — (2) — Derivatives designated as net investment hedges Cross-currency swap contracts gain/(loss): Recognized in Other comprehensive (loss)/income 23 34 50 35 Foreign exchange contracts gain/(loss): Recognized in Other comprehensive (loss)/income 18 — 41 — Non-derivatives designated as net investment hedges Non-U.S. dollar borrowings gain/(loss): Recognized in Other comprehensive (loss)/income — — — (10)

FINANCING ARRANGEMENTS (Tables)

FINANCING ARRANGEMENTS (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Short-term Debt	Short-term debt obligations include: Dollars in millions June 30, December 31, Commercial paper borrowings $ 266 $ — Non-U.S. short-term financing obligations 173 170 Current portion of Long-term debt 3,092 2,873 Other — 76 Short-term debt obligations $ 3,531 $ 3,119
Schedule of Long-term Debt and Current Portion of Long-term Debt	Long-term debt and the current portion of Long-term debt include: Dollars in millions June 30, December 31, Principal value $ 51,449 $ 38,886 Adjustments to principal value: Fair value of interest rate swap contracts (17) (11) Unamortized basis adjustment from swap terminations 76 82 Unamortized bond discounts and issuance costs (405) (303) Unamortized purchase price adjustments of Celgene debt 847 872 Total $ 51,950 $ 39,526 Current portion of Long-term debt $ 3,092 $ 2,873 Long-term debt 48,858 36,653 Total $ 51,950 $ 39,526 During the first quarter of 2024, BMS issued an aggregate principal amount of $13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $12.9 billion, consisting of: Principal Amount (in millions) Floating rate notes due 2026 (a) $ 500 4.950% Notes due 2026 1,000 4.900% Notes due 2027 1,000 4.900% Notes due 2029 1,750 5.100% Notes due 2031 1,250 5.200% Notes due 2034 2,500 5.500% Notes due 2044 500 5.550% Notes due 2054 2,750 5.650% Notes due 2064 1,750 Total $ 13,000 (a) As of June 30, 2024, floating rate equals SOFR+0.49%.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	6 Months Ended
	Jun. 30, 2024
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Schedule of Receivables	Dollars in millions June 30, December 31, Trade receivables $ 10,471 $ 9,551 Less: charge-backs and cash discounts (686) (646) Less: allowance for expected credit loss (39) (23) Net trade receivables 9,746 8,882 Alliance, royalties, VAT and other 1,677 2,039 Receivables $ 11,423 $ 10,921

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory, Net [Abstract]
Inventories	Dollars in millions June 30, December 31, Finished goods $ 862 $ 663 Work in process 2,807 2,430 Raw and packaging materials 437 475 Total inventories $ 4,106 $ 3,568 Inventories $ 3,077 $ 2,662 Other non-current assets 1,029 906

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Dollars in millions June 30, December 31, Land $ 162 $ 162 Buildings 6,670 6,495 Machinery, equipment and fixtures 3,845 3,717 Construction in progress 1,255 1,075 Gross property, plant and equipment 11,932 11,449 Less accumulated depreciation (5,087) (4,803) Property, plant and equipment $ 6,845 $ 6,646

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amounts in Goodwill were as follows: Dollars in millions Balance at December 31, 2023 $ 21,169 Acquisitions (Note 4) 580 Currency translation and other adjustments (17) Balance at June 30, 2024 $ 21,732
Schedule of Other Intangible Assets	Other intangible assets consisted of the following: Estimated June 30, 2024 December 31, 2023 Dollars in millions Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net R&D technology (a) 6 years $ 1,980 $ (110) $ 1,870 $ — $ — $ — Acquired marketed product rights (a) 3 – 15 years 63,473 (44,726) 18,747 63,076 (40,184) 22,892 Capitalized software 3 – 10 years 1,532 (1,096) 436 1,497 (1,027) 470 IPRD (a) 8,375 — 8,375 3,710 — 3,710 Total $ 75,360 $ (45,932) $ 29,428 $ 68,283 $ (41,211) $ 27,072 (a) Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements."

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2024
Supplemental Financial Information [Abstract]
Schedule of Other Current Assets	Dollars in millions June 30, December 31, 2023 Income taxes $ 3,337 $ 3,927 Research and development 799 723 Contract assets 386 416 Restricted cash (a) 2 55 Other 1,213 786 Other current assets $ 5,737 $ 5,907
Schedule of Other Assets, Noncurrent	Dollars in millions June 30, December 31, 2023 Equity investments (Note 9) $ 2,000 $ 1,699 Operating leases 1,316 1,390 Inventories (Note 12) 1,029 906 Pension and postretirement 210 284 Research and development 411 413 Restricted cash (a) 1 — Receivables and convertible notes 642 436 Other 462 242 Other non-current assets $ 6,071 $ 5,370
Schedule of Other Current Liabilities	Dollars in millions June 30, December 31, 2023 Rebates and discounts $ 7,686 $ 7,680 Income taxes 1,474 1,371 Employee compensation and benefits 921 1,291 Research and development 1,231 1,257 Dividends 1,217 1,213 Interest 591 349 Royalties 422 465 Operating leases 177 162 Other 2,264 2,096 Other current liabilities $ 15,983 $ 15,884
Other Noncurrent Liabilities	Dollars in millions June 30, December 31, 2023 Income taxes $ 1,783 $ 3,288 Pension and postretirement 466 480 Operating leases 1,438 1,530 Deferred income 263 300 Deferred compensation 467 427 Contingent value rights 248 — Other 328 396 Other non-current liabilities $ 4,993 $ 6,421

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Stock by Class	The following table summarizes changes in equity during the six months ended June 30, 2024: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and shares in millions Shares Par Value Shares Cost Balance at December 31, 2023 2,923 $ 292 $ 45,684 $ (1,546) $ 28,766 902 $ (43,766) $ 55 Net (loss)/earnings — — — — (11,911) — — 3 Other comprehensive income/(loss) — — — 146 — — — — Cash dividends declared $0.60 per share — — — — (1,215) — — — Stock compensation — — (29) — — (6) 69 — Balance at March 31, 2024 2,923 $ 292 $ 45,655 $ (1,400) $ 15,640 896 $ (43,697) $ 58 Net earnings — — — — 1,680 — — 4 Other comprehensive loss — — — (56) — — — — Cash dividends declared $0.60 per share — — — — (1,217) — — — Stock compensation — — 111 — — — 7 — Distributions — — — — — — — (8) Balance at June 30, 2024 2,923 $ 292 $ 45,766 $ (1,456) $ 16,103 896 $ (43,690) $ 54 The following table summarizes changes in equity during the six months ended June 30, 2023: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and shares in millions Shares Par Value Shares Cost Balance at December 31, 2022 2,923 $ 292 $ 45,165 $ (1,281) $ 25,503 825 $ (38,618) $ 57 Net earnings — — — — 2,262 — — 5 Other comprehensive income/(loss) — — — (87) — — — — Cash dividends declared $0.57 per share — — — — (1,197) — — — Share repurchase program — — — — — 4 (250) — Stock compensation — — (25) — — (6) 60 — Balance at March 31, 2023 2,923 $ 292 $ 45,140 $ (1,368) $ 26,568 823 $ (38,808) $ 62 Net earnings — — — — 2,073 — — 4 Other comprehensive income — — — (19) — — — — Cash dividends declared $0.57 per share — — — — (1,192) — — — Stock repurchase program — — — — — 13 (911) — Stock compensation — — 159 — — (2) 39 — Distributions — — — — — — — (9) Balance at June 30, 2023 2,923 292 45,299 (1,387) 27,449 834 (39,680) 57
Schedule of Comprehensive Income Loss	The following table summarizes the changes in Other comprehensive income by component: Three Months Ended June 30, 2024 Six Months Ended June 30, 2024 Dollars in millions Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges Recognized in Other comprehensive income/(loss) $ 84 $ (12) $ 72 $ 338 $ (59) $ 279 Reclassified to net earnings (a) (20) 2 (18) (35) 1 (34) Derivatives qualifying as cash flow hedges 64 (10) 54 303 (58) 245 Pension and postretirement benefits Actuarial gains/(losses) (87) 21 (66) (93) 22 (71) Amortization (b) 1 — 1 3 — 3 Settlements (b) — 1 1 19 (2) 17 Pension and postretirement benefits (86) 22 (64) (71) 20 (51) Unrealized losses on marketable debt securities (1) 1 — (3) 1 (2) Foreign currency translation (37) (9) (46) (81) (21) (102) Other comprehensive income/(loss) $ (60) $ 4 $ (56) $ 148 $ (58) $ 90 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Dollars in millions Pretax Tax After Tax Pretax Tax After Tax Derivatives qualifying as cash flow hedges Recognized in Other comprehensive income/(loss) $ 94 $ (16) $ 78 $ 81 $ (13) $ 68 Reclassified to net earnings (a) (86) 11 (75) (219) 30 (189) Derivatives qualifying as cash flow hedges 8 (5) 3 (138) 17 (121) Pension and postretirement benefits Actuarial gains/(losses) (13) 2 (11) (13) 2 (11) Foreign currency translation (4) (7) (11) 31 (5) 26 Other comprehensive income/(loss) $ (9) $ (10) $ (19) $ (120) $ 14 $ (106) (a) Included in Cost of products sold and Other (income)/expense, net. Refer to "—Note 9. Financial Instruments and Fair Value Measurements" for further information. (b) Included in Other (income)/expense, net.
Schedule of Accumulated Other Comprehensive Income Loss	The accumulated balances related to each component of Other comprehensive (loss)/income, net of taxes, were as follows: Dollars in millions June 30, December 31, Derivatives qualifying as cash flow hedges $ 247 $ 2 Pension and postretirement benefits (789) (738) Marketable debt securities — 2 Foreign currency translation (a) (914) (812) Accumulated other comprehensive loss $ (1,456) $ (1,546) (a) Includes net investment hedge gains of $215 million and $144 million as of June 30, 2024 and December 31, 2023, respectively.

EMPLOYEE STOCK BENEFIT PLANS (T

EMPLOYEE STOCK BENEFIT PLANS (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Cost by Plan	Stock-based compensation expense was as follows: Three Months Ended June 30, Six Months Ended June 30, Dollars in millions 2024 2023 2024 2023 Cost of products sold $ 14 $ 13 $ 28 $ 24 Marketing, selling and administrative 48 56 101 107 Research and development 63 68 129 128 Total Stock-based compensation expense $ 125 $ 137 $ 258 $ 259 Income tax benefit (a) $ 27 $ 27 $ 55 $ 52 (a) Income tax benefit excludes excess tax (deficiencies)/benefits from share-based compensation awards that were vested or exercised of $(3) million and $(20) million for the three and six months ended June 30, 2024, and $2 million and $20 million for the three and six months ended June 30, 2023, respectively.
Schedule Of Share Based Compensation Additional Information	The number of units granted and the weighted-average fair value on the grant date for the six months ended June 30, 2024 were as follows: Units in millions Units Weighted-Average Fair Value Restricted stock units 13.0 $ 47.54 Market share units 1.3 $ 58.63 Performance share units 1.9 $ 53.08
Share-based Payment Arrangement, Nonvested Award, Cost	Dollars in millions Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 1,075 $ 90 $ 123 Expected weighted-average period in years of compensation cost to be recognized 2.9 2.6 2.1

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Total Revenues	$ 12,201	$ 11,226	$ 24,066	$ 22,563
Net product sales
Disaggregation of Revenue [Line Items]
Total Revenues	11,925	10,917	23,484	21,965
Alliance revenues
Disaggregation of Revenue [Line Items]
Total Revenues	116	179	250	323
Other revenues
Disaggregation of Revenue [Line Items]
Total Revenues	$ 160	$ 130	$ 332	$ 275

REVENUE - Reconciliation of Gro

REVENUE - Reconciliation of Gross Product Sales to Net Product Sales (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Gross to Net Adjustments [Line Items]
Total Revenues	$ 12,201	$ 11,226	$ 24,066	$ 22,563
Total GTN adjustments	(8,855)	(7,194)	(16,591)	(13,434)
Prior period gross to net adjustment impacted by new accounting pronouncement	(19)	11	61	98
United States
Gross to Net Adjustments [Line Items]
Total Revenues	8,801	7,804	17,277	15,756
Total GTN adjustments	(8,000)	(6,400)	(14,900)	(11,900)
Gross product sales
Gross to Net Adjustments [Line Items]
Total Revenues	20,780	18,111	40,075	35,399
Net product sales
Gross to Net Adjustments [Line Items]
Total Revenues	11,925	10,917	23,484	21,965
Charge-backs and cash discounts
Gross to Net Adjustments [Line Items]
Total GTN adjustments	(2,843)	(2,279)	(5,399)	(4,370)
Medicaid and Medicare rebates
Gross to Net Adjustments [Line Items]
Total GTN adjustments	(3,864)	(3,143)	(6,948)	(5,625)
Other rebates, returns, discounts and adjustments
Gross to Net Adjustments [Line Items]
Total GTN adjustments	$ (2,148)	$ (1,772)	$ (4,244)	$ (3,439)

REVENUE - Disaggregation of R_2

REVENUE - Disaggregation of Revenue by Product and Region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue from External Customer [Line Items]
Total Revenues	$ 12,201	$ 11,226	$ 24,066	$ 22,563
Performance obligation satisfied in previous period	76	75	258	241
United States
Revenue from External Customer [Line Items]
Total Revenues	8,801	7,804	17,277	15,756
International
Revenue from External Customer [Line Items]
Total Revenues	3,224	3,247	6,414	6,477
Other
Revenue from External Customer [Line Items]
Total Revenues	176	175	375	330
Growth Portfolio
Revenue from External Customer [Line Items]
Total Revenues	5,596	4,743	10,388	9,161
Opdivo
Revenue from External Customer [Line Items]
Total Revenues	2,387	2,145	4,465	4,347
Orencia
Revenue from External Customer [Line Items]
Total Revenues	948	927	1,746	1,691
Yervoy
Revenue from External Customer [Line Items]
Total Revenues	630	585	1,213	1,093
Reblozyl
Revenue from External Customer [Line Items]
Total Revenues	425	234	779	440
Opdualag
Revenue from External Customer [Line Items]
Total Revenues	235	154	441	271
Abecma
Revenue from External Customer [Line Items]
Total Revenues	95	132	177	279
Zeposia
Revenue from External Customer [Line Items]
Total Revenues	151	100	261	178
Breyanzi
Revenue from External Customer [Line Items]
Total Revenues	153	100	260	171
Camzyos
Revenue from External Customer [Line Items]
Total Revenues	139	46	223	75
Sotyktu
Revenue from External Customer [Line Items]
Total Revenues	53	25	97	41
Augtyro
Revenue from External Customer [Line Items]
Total Revenues	7	0	13	0
Krazati
Revenue from External Customer [Line Items]
Total Revenues	32	0	53	0
Other Growth products
Revenue from External Customer [Line Items]
Total Revenues	341	295	660	575
Legacy Portfolio
Revenue from External Customer [Line Items]
Total Revenues	6,605	6,483	13,678	13,402
Eliquis
Revenue from External Customer [Line Items]
Total Revenues	3,416	3,204	7,136	6,627
Revlimid
Revenue from External Customer [Line Items]
Total Revenues	1,353	1,468	3,022	3,218
Pomalyst/Imnovid
Revenue from External Customer [Line Items]
Total Revenues	959	847	1,824	1,679
Sprycel
Revenue from External Customer [Line Items]
Total Revenues	424	458	798	887
Abraxane
Revenue from External Customer [Line Items]
Total Revenues	231	258	448	497
Other Legacy products
Revenue from External Customer [Line Items]
Total Revenues	$ 222	$ 248	$ 450	$ 494

ALLIANCES - Selected Financial

ALLIANCES - Selected Financial Information For Alliances (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Alliance Statement [Line Items]
Total Revenues		$ 12,201	$ 11,226	$ 24,066	$ 22,563
Cost of products sold	[1]	3,267	2,876	6,199	5,442
Marketing, selling and administrative		(1,928)	(1,934)	(4,295)	(3,696)
Other (income)/expense, net		273	(116)	354	(529)
Receivables – from alliance partners		11,423		11,423		$ 10,921
Accounts payable – to alliance partners		3,751		3,751		3,259
Net product sales
Alliance Statement [Line Items]
Total Revenues		11,925	10,917	23,484	21,965
Alliance revenues
Alliance Statement [Line Items]
Total Revenues		116	179	250	323
Collaborative Arrangement
Alliance Statement [Line Items]
Total Revenues		3,586	3,499	7,482	7,175
Cost of products sold		1,692	1,614	3,517	3,320
Marketing, selling and administrative		(65)	(64)	(144)	(138)
Research and development		46	36	100	80
Acquired IPRD		80	55	880	55
Other (income)/expense, net		(102)	(15)	(114)	(27)
Receivables – from alliance partners		290		290		233
Accounts payable – to alliance partners		1,627		1,627		1,394
Deferred income - from alliances		248		248		$ 274
Collaborative Arrangement | Net product sales
Alliance Statement [Line Items]
Total Revenues		$ 3,470	$ 3,320	$ 7,232	$ 6,852
[1]Excludes amortization of acquired intangible assets

ALLIANCES - Additional Informat

ALLIANCES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
SystImmune
Alliance Statement [Line Items]
Upfront fee made to collaborative partner		$ 800
Consideration for contingent development and regulatory approval		$ 7,600
Eisai
Alliance Statement [Line Items]
Collaboration arrangement, termination payment received	$ 90

ACQUISITIONS, DIVESTITURES, L_3

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions				6 Months Ended	12 Months Ended	36 Months Ended
	Mar. 18, 2024 USD ($) $ / shares	Feb. 26, 2024 USD ($) $ / shares	Jan. 23, 2024 USD ($) right $ / shares	Jun. 30, 2024 USD ($)	Dec. 31, 2023	Dec. 31, 2026
Licensing Arrangements [Line Items]
Business combination, contingent value, number of rights received | right			1
Keytruda royalties
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner					6.50%
Keytruda royalties | Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner						2.50%
Keytruda royalties | Forecast | Bristol-Myers Squibb
Licensing Arrangements [Line Items]
Payment and royalty allocation						75%
Keytruda royalties | Forecast | Ono
Licensing Arrangements [Line Items]
Payment and royalty allocation						25%
RayzeBio
Licensing Arrangements [Line Items]
Share price (in usd per share) | $ / shares		$ 62.50
Total consideration		$ 4,147
Business combination, consideration transferred		3,600
Intangible assets		3,700
RayzeBio | IPRD
Licensing Arrangements [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets		1,700
RayzeBio | R&D technology
Licensing Arrangements [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets		2,000
RayzeBio | Unvested Equity Awards
Licensing Arrangements [Line Items]
Total consideration		$ 274
Mirati Therapeutics
Licensing Arrangements [Line Items]
Share price (in usd per share) | $ / shares			$ 58
Total consideration			$ 4,801
Business combination, consideration transferred			$ 4,100
Business combination, contingent value, share price (in dollars per share) | $ / shares			$ 12
Continent consideration liability			$ 1,000
Business combination, contingent value payout, period			7 years
Inventories			$ 215
Intangible assets			4,225
Mirati Therapeutics | IPRD
Licensing Arrangements [Line Items]
Intangible assets			3,500
Mirati Therapeutics | Acquired marketed product rights
Licensing Arrangements [Line Items]
Intangible assets			640
Mirati Therapeutics | Unvested Equity Awards
Licensing Arrangements [Line Items]
Total consideration			$ 114
Inventory Purchase Price Fair Value Adjustment
Licensing Arrangements [Line Items]
Inventories				$ 148
Karuna
Licensing Arrangements [Line Items]
Asset acquisition, share price (in dollars per share) | $ / shares	$ 330
Payments for asset acquisitions	$ 14,027
Payments for asset acquisitions, net of cash acquired	12,900
Karuna | Vested Equity Awards
Licensing Arrangements [Line Items]
Payments for asset acquisitions	1,100
Karuna | Unvested Equity Awards
Licensing Arrangements [Line Items]
Payments for asset acquisitions	$ 289
Karuna | Acquired IPRD
Licensing Arrangements [Line Items]
Payments for asset acquisitions				$ 12,100

ACQUISITIONS, DIVESTITURES, L_4

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Assets Acquired and Liabilities Assumed in Karuna Acquisition (Details) - Karuna - USD ($) $ in Millions		6 Months Ended
	Mar. 18, 2024	Jun. 30, 2024
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions	$ 14,027
Transaction costs	55
Total consideration allocated	13,793
Cash and cash equivalents	1,167
Other assets	67
Intangible assets	100
Deferred income tax asset	542
Deferred income tax liability	(25)
Other liabilities	(180)
Total identifiable assets acquired, net	1,671
IPRD
Asset Acquisition, Contingent Consideration [Line Items]
Intangible assets	12,122
Common Stock
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions	12,606
Equity
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions	1,421
Unvested Equity Awards
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions	$ 289
Unvested Equity Awards | Research and development
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions		$ 159
Unvested Equity Awards | Marketing, selling and administrative
Asset Acquisition, Contingent Consideration [Line Items]
Payments for asset acquisitions		$ 130

ACQUISITIONS, DIVESTITURES, L_5

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Consideration for RayzeBio Acquisition (Details) - RayzeBio - USD ($) $ in Millions		6 Months Ended
	Feb. 26, 2024	Jun. 30, 2024
Business Acquisition [Line Items]
Total consideration	$ 4,147
Total consideration allocated	3,873
Common Stock
Business Acquisition [Line Items]
Total consideration	3,851
Equity
Business Acquisition [Line Items]
Total consideration	296
Unvested Equity Awards
Business Acquisition [Line Items]
Total consideration	$ 274
Unvested Equity Awards | Research and development
Business Acquisition [Line Items]
Total consideration		$ 115
Unvested Equity Awards | Marketing, selling and administrative
Business Acquisition [Line Items]
Total consideration		$ 159

ACQUISITIONS, DIVESTITURES, L_6

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Purchase Price Allocation of RayzeBio Acquisition (Details) - USD ($) $ in Millions	Jun. 30, 2024	Feb. 26, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 21,732		$ 21,169
RayzeBio
Business Acquisition [Line Items]
Cash and cash equivalents		$ 501
Other assets		70
Intangible assets		3,700
Deferred income tax asset		81
Deferred income tax liability		(798)
Other liabilities		(109)
Identifiable net assets acquired		3,445
Goodwill		428
Total consideration allocated		$ 3,873

ACQUISITIONS, DIVESTITURES, L_7

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Consideration for Mirati Acquisition (Details) - Mirati Therapeutics - USD ($) $ in Millions		6 Months Ended
	Jan. 23, 2024	Jun. 30, 2024
Business Acquisition [Line Items]
Total consideration	$ 4,801
Plus: Fair value of CVRs	248
Total consideration allocated	4,935
Common Stock
Business Acquisition [Line Items]
Total consideration	4,596
Equity
Business Acquisition [Line Items]
Total consideration	205
Unvested Equity Awards
Business Acquisition [Line Items]
Total consideration	$ 114
Unvested Equity Awards | Research and development
Business Acquisition [Line Items]
Total consideration		$ 54
Unvested Equity Awards | Marketing, selling and administrative
Business Acquisition [Line Items]
Total consideration		$ 60

ACQUISITIONS, DIVESTITURES, L_8

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Purchase Price Allocation of Mirati Acquisition (Details) - USD ($) $ in Millions	Jun. 30, 2024	Jan. 23, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 21,732		$ 21,169
Mirati Therapeutics
Business Acquisition [Line Items]
Cash and cash equivalents		$ 748
Inventories		215
Other assets		159
Intangible assets		4,225
Deferred income tax asset		734
Deferred income tax liability		(1,094)
Other liabilities		(204)
Identifiable net assets acquired		4,783
Goodwill		152
Total consideration allocated		$ 4,935

ACQUISITIONS, DIVESTITURES, L_9

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Divestitures (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Business Acquisition [Line Items]
Net Proceeds	$ 265	$ 188	$ 496	$ 408
Divestiture gains (Note 4)	0	0	0	0
Royalty Income	(265)	(218)	(536)	(406)
Diabetes business - royalties
Business Acquisition [Line Items]
Net Proceeds	265	185	496	401
Divestiture gains (Note 4)	0	0	0	0
Royalty Income	(265)	(218)	(536)	(406)
Mature products and other
Business Acquisition [Line Items]
Net Proceeds	0	3	0	7
Divestiture gains (Note 4)	0	0	0	0
Royalty Income	$ 0	$ 0	$ 0	$ 0

ACQUISITIONS, DIVESTITURES, _10

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Licensing and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent milestone income	$ (25)	$ (5)	$ (25)	$ (36)
Amortization of deferred income	(12)	(15)	(24)	(27)
Royalty and licensing income	(191)	(340)	(352)	(703)
Keytruda royalties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty income, nonoperating	(137)	(284)	(270)	(563)
Tecentriq royalties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty income, nonoperating	(11)	(24)	(23)	(54)
Other royalties and licensing income
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty income, nonoperating	$ (6)	$ (12)	$ (10)	$ (23)

OTHER (INCOME)_EXPENSE, NET - S

OTHER (INCOME)/EXPENSE, NET - Schedule Of Other Income Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Alliance Statement [Line Items]
Interest expense (Note 10)	$ 521	$ 282	$ 946	$ 570
Royalty and licensing income (Note 4)	(191)	(340)	(352)	(703)
Royalty income - divestiture (Note 4)	(265)	(218)	(536)	(406)
Investment income	(87)	(95)	(270)	(197)
Litigation and other settlements (a)	69	(7)	71	(332)
Provision for restructuring (Note 6)	260	113	480	180
Integration expenses	74	59	145	126
Equity investment (gain)/losses (Note 9)	(107)	58	(209)	213
Acquisition expense (Note 4)	1	0	50	0
Other	(2)	32	29	20
Other (income)/expense, net	273	$ (116)	$ 354	(529)
Nimbus Therapuetics TYK2 Inhibitor
Alliance Statement [Line Items]
Other				$ 400
Eisai
Alliance Statement [Line Items]
Collaboration arrangement, termination payment received	$ 90

RESTRUCTURING - Additional Info

RESTRUCTURING - Additional Information (Details) $ in Millions	Jun. 30, 2024 USD ($)
2023 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring and related charges	$ 1,500
Celgene and Other Acquisition Plans
Restructuring Cost and Reserve [Line Items]
Expected restructuring and related charges	$ 400

RESTRUCTURING - Schedule of Res

RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total charges	$ 357	$ 234	$ 669	$ 369
Employee termination costs	260	109	477	174
Provision for restructuring	260	113	480	180
Integration expenses	74	59	145	126
Accelerated depreciation	20	12	34	13
Asset impairments	0	50	2	50
Other termination costs
Restructuring Cost and Reserve [Line Items]
Other termination costs	0	4	3	6
Other shutdown costs
Restructuring Cost and Reserve [Line Items]
Other termination costs	3	0	8	0
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Total charges	3	36	17	37
Marketing, selling and administrative
Restructuring Cost and Reserve [Line Items]
Total charges	6	20	12	20
Research and development
Restructuring Cost and Reserve [Line Items]
Total charges	14	6	15	6
Other (income)/expense, net
Restructuring Cost and Reserve [Line Items]
Total charges	334	172	625	306
2023 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Total charges	264	170	332	231
Celgene and Other Acquisition Plans
Restructuring Cost and Reserve [Line Items]
Total charges	$ 93	$ 64	$ 337	$ 138

RESTRUCTURING - Schedule of R_2

RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Restructuring Reserve [Roll Forward]
Beginning balance	$ 188	$ 47
Provision for restructuring	480	180
Foreign currency translation and other	(3)	1
Payments	(234)	(48)
Ending balance	$ 431	$ 180

INCOME TAXES - Schedule of Prov

INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Earnings/(loss) before income taxes	$ 1,286	$ 1,859	$ (10,230)	$ 4,629
Income tax (benefit)/provision	$ (398)	$ (218)	$ (6)	$ 285
Effective tax rate	(30.90%)	(11.70%)	0.10%	6.20%

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Income tax reserves	$ 644			$ 89
Effective income tax rate reconciliation, nondeductible expense, amount			$ 12,100
Effective income tax rate reconciliation, deduction, impairment of subsidiary investments		$ 656		656
Income tax payments			2,100	3,100
Transition taxes paid			799	$ 567
Minimum
Effective Income Tax Rate Reconciliation [Line Items]
Reasonably possible decrease in unrecognized tax benefits	110		110
Maximum
Effective Income Tax Rate Reconciliation [Line Items]
Reasonably possible decrease in unrecognized tax benefits	$ 150		$ 150

EARNINGS_(LOSS) PER SHARE (Deta

EARNINGS/(LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net earnings/(loss) attributable to BMS	$ 1,680	$ 2,073	$ (10,231)	$ 4,335
Weighted-average common shares outstanding - basic (in shares)	2,027,000,000	2,093,000,000	2,025,000,000	2,096,000,000
Incremental shares attributable to share-based compensation plans (in shares)	2,000,000	9,000,000	0	11,000,000
Weighted-average common shares outstanding - diluted (in shares)	2,029,000,000	2,102,000,000	2,025,000,000	2,107,000,000
Earnings/(Loss) per common share
Basic (usd per share)	$ 0.83	$ 0.99	$ (5.05)	$ 2.07
Diluted (usd per share)	$ 0.83	$ 0.99	$ (5.05)	$ 2.06
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	39,000,000	0	44,000,000	0

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	$ 593	$ 459
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and other securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liability	0	0
Level 1 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	494	318
Level 1 | Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	2	4
Level 1 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 1 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 1 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and other securities	4,004	8,489
Derivative assets	456	219
Derivative liabilities	114	160
Contingent consideration liability	0	0
Level 2 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	99	141
Level 2 | Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	0	0
Level 2 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	201	609
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	92
Level 2 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	475	460
Level 2 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	41	19
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and other securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liability	0	8
Level 3 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments	0	0
Level 3 | Contingent value rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	248	0
Level 3 | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 3 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	0	0
Level 3 | U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Summary of Equity Investments Carrying Amount (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Equity investments with readily determinable fair values	$ 593	$ 459
Equity investments without readily determinable fair values	785	698
Limited partnerships and other equity method investments	622	542
Total equity investments	$ 2,000	$ 1,699

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Equity investments with RDFV
Net (gain)/loss recognized	$ (36)	$ 47	$ (122)	$ 188
Less: net (gain)/loss recognized on investments sold	0	(11)	1	(12)
Net unrealized (gain)/loss recognized on investments still held	(36)	58	(123)	200
Equity investments without RDFV
Upward adjustments	(11)	0	(21)	(6)
Net realized (gain)/loss recognized on investments sold	(36)	0	(36)	0
Impairments and downward adjustments	4	0	29	0
Equity in net (income)/loss of affiliates	(28)	11	(59)	31
Total equity investment (gains)/losses	$ (107)	$ 58	$ (209)	$ 213

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Additional Information (Details) € in Millions, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 EUR (€)
Derivative [Line Items]
Debt securities, available-for-sale, term		5 years		5 years		4 years
Cumulative upward adjustments		$ 207		$ 207
Cumulative impairment amount		85		85
Pre-tax gains				80
Recognized in Other comprehensive (loss)/income		84	$ 94	338	$ 81
Principal value		51,449		51,449		$ 38,886
Cross-currency swap contracts
Derivative [Line Items]
Recognized in Other comprehensive (loss)/income		(18)	$ 34	(34)	$ 28
Forward interest rate contracts | Cash Flow Hedging
Derivative [Line Items]
Derivative, notional amount	$ 5,000
Recognized in Other comprehensive (loss)/income	$ 131
Designated as cash flow hedges
Derivative [Line Items]
Principal value | €							€ 375
Designated as cash flow hedges | Cross-currency swap contracts | Cash Flow Hedging
Derivative [Line Items]
Derivative, notional amount		1,200		1,200
Designated as cash flow hedges | Cross Currency Interest Rate And Foreign Currency Forward Contracts
Derivative [Line Items]
Derivative, notional amount		1,600		1,600
Euro Member Countries, Euro | Designated as cash flow hedges | Foreign Exchange Contract
Derivative [Line Items]
Derivative, notional amount		4,200		4,200
Euro Member Countries, Euro | Designated as cash flow hedges | Cross Currency Interest Rate And Foreign Currency Forward Contracts | Net Investment Hedging
Derivative [Line Items]
Derivative, notional amount		593		593
Japan, Yen | Designated as cash flow hedges | Foreign Exchange Contract
Derivative [Line Items]
Derivative, notional amount		1,200		1,200
Japan, Yen | Designated as cash flow hedges | Cross Currency Interest Rate And Foreign Currency Forward Contracts
Derivative [Line Items]
Derivative, notional amount		$ 660		$ 660

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivatives and Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Interest rate swap contracts
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ (17)	$ (11)
Designated as cash flow hedges | Foreign currency exchange contracts | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative assets	256	130
Derivative liabilities	(8)	(66)
Designated as cash flow hedges | Foreign currency exchange contracts | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative assets	36	0
Derivative liabilities	(2)	(8)
Designated as cash flow hedges | Foreign currency exchange contracts | Assets | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	6,115	4,772
Designated as cash flow hedges | Foreign currency exchange contracts | Assets | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	505	0
Designated as cash flow hedges | Foreign currency exchange contracts | Liability | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	403	1,971
Designated as cash flow hedges | Foreign currency exchange contracts | Liability | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	377	215
Designated as cash flow hedges | Cross-currency swap contracts | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	1,200
Derivative assets	24	50
Derivative liabilities	(8)	0
Designated as cash flow hedges | Cross-currency swap contracts | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative assets	29	0
Derivative liabilities	(13)	(43)
Designated as cash flow hedges | Cross-currency swap contracts | Assets | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	583	1,210
Designated as cash flow hedges | Cross-currency swap contracts | Assets | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	396	0
Designated as cash flow hedges | Cross-currency swap contracts | Liability | Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	627	0
Designated as cash flow hedges | Cross-currency swap contracts | Liability | Net Investment Hedging
Derivatives, Fair Value [Line Items]
Derivative, notional amount	292	747
Designated as cash flow hedges | Interest rate swap contracts
Derivatives, Fair Value [Line Items]
Derivative assets	1	3
Derivative liabilities	(18)	(14)
Designated as cash flow hedges | Interest rate swap contracts | Assets
Derivatives, Fair Value [Line Items]
Derivative, notional amount	1,000	2,500
Designated as cash flow hedges | Interest rate swap contracts | Liability
Derivatives, Fair Value [Line Items]
Derivative, notional amount	2,255	1,755
Not designated as hedges | Foreign currency exchange contracts
Derivatives, Fair Value [Line Items]
Derivative assets	103	20
Derivative liabilities	(65)	(29)
Not designated as hedges | Foreign currency exchange contracts | Assets
Derivatives, Fair Value [Line Items]
Derivative, notional amount	3,122	906
Not designated as hedges | Foreign currency exchange contracts | Liability
Derivatives, Fair Value [Line Items]
Derivative, notional amount	1,749	1,250
Not designated as hedges | Total return swap contracts
Derivatives, Fair Value [Line Items]
Derivative assets	7	16
Derivative liabilities	0	0
Not designated as hedges | Total return swap contracts | Assets
Derivatives, Fair Value [Line Items]
Derivative, notional amount	441	401
Not designated as hedges | Total return swap contracts | Liability
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_8

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Derivative Instruments, Gain (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Interest rate swap contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	$ (29)	$ (90)	$ (74)	$ (210)
Interest rate swap contracts | Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	(40)	(44)	(53)	(60)
Cross-currency swap contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	0	0	0	0
Cross-currency swap contracts | Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	7	(5)	36	(28)
Foreign currency exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	0	0	0	0
Foreign currency exchange contracts | Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	4	$ (4)	7	$ (7)
Forward interest rate contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	0		0
Forward interest rate contracts | Other (income)/expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	$ (1)		$ (2)

FINANCIAL INSTRUMENTS AND FAI_9

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Gain/(Loss) on Hedging Activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Foreign exchange contracts gain/(loss):
Recognized in Other comprehensive (loss)/income	$ 84	$ 94	$ 338	$ 81
Reclassified to net earnings, pretax	(20)	(86)	(35)	(219)
Non-U.S. dollar borrowings gain/(loss):
Recognized in Other comprehensive (loss)/income	(37)	(4)	(81)	31
Designated as cash flow hedges
Non-U.S. dollar borrowings gain/(loss):
Recognized in Other comprehensive (loss)/income	0	0	0	(10)
Foreign currency exchange contracts
Foreign exchange contracts gain/(loss):
Recognized in Other comprehensive (loss)/income	102	60	241	53
Derivatives designated as net investment hedges
Recognized in Other comprehensive (loss)/income	18	0	41	0
Foreign currency exchange contracts | Cost of products sold
Foreign exchange contracts gain/(loss):
Reclassified to net earnings, pretax	(29)	(90)	(74)	(210)
Cross-currency swap contracts
Foreign exchange contracts gain/(loss):
Recognized in Other comprehensive (loss)/income	(18)	34	(34)	28
Derivatives designated as net investment hedges
Recognized in Other comprehensive (loss)/income	23	34	50	35
Cross-currency swap contracts | Other (income)/expense, net
Foreign exchange contracts gain/(loss):
Reclassified to net earnings, pretax	10	4	41	(9)
Interest rate swap contracts
Foreign exchange contracts gain/(loss):
Recognized in Other comprehensive (loss)/income	0	0	131	0
Interest rate swap contracts | Other operating income (expense)
Foreign exchange contracts gain/(loss):
Reclassified to net earnings, pretax	$ (1)	$ 0	$ (2)	$ 0

FINANCING ARRANGEMENTS - Short-

FINANCING ARRANGEMENTS - Short-Term Debt (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Commercial paper borrowings	$ 266	$ 0
Non-U.S. short-term financing obligations	173	170
Current portion of Long-term debt	3,092	2,873
Other	0	76
Short-term debt obligations	$ 3,531	$ 3,119

FINANCING ARRANGEMENTS - Additi

FINANCING ARRANGEMENTS - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Proceeds from issuance of short-term debt obligations			$ 3,000,000,000	$ 2,987,000,000	$ 0
Repayments of short-term debt obligations		$ 2,700,000,000		2,731,000,000	0
Long-term debt, fair value		47,700,000,000		47,700,000,000		$ 36,700,000,000
Principal value		51,449,000,000		51,449,000,000		38,886,000,000
Debt matured and repaid					1,900,000,000
Interest payments				735,000,000	639,000,000
Commercial Paper Program | Commercial paper
Debt Instrument [Line Items]
Debt instrument, maximum amount authorized for issuance		$ 7,000,000,000		$ 7,000,000,000
Debt instrument, term				365 days
Short-term debt, weighted average interest rate, at point in time		5.43%		5.43%
3.625% Notes
Debt Instrument [Line Items]
Debt matured and repaid				$ 395,000,000
Interest rates		3.625%		3.625%
2.750% Notes
Debt Instrument [Line Items]
Debt matured and repaid					$ 750,000,000
Interest rates					2.75%
3.250% Notes
Debt Instrument [Line Items]
Debt matured and repaid					$ 890,000,000
Interest rates					3.25%
7.150% Notes
Debt Instrument [Line Items]
Debt matured and repaid					$ 239,000,000
Interest rates					7.15%
Unsecured Debt | Line of Credit
Debt Instrument [Line Items]
Debt instrument, term	364 days
Principal value	$ 10,000,000,000
$5 Billion Maximum Borrowing Capacity
Debt Instrument [Line Items]
Long-term debt, term (in years)		5 years		5 years
Line of credit facility, maximum borrowing capacity		$ 5,000,000,000		$ 5,000,000,000
Renewal period (in years)		1 year		1 year
$2 Billion Maximum Borrowing Capacity
Debt Instrument [Line Items]
Long-term debt, term (in years)		364 days		364 days
Line of credit facility, maximum borrowing capacity		$ 2,000,000,000		$ 2,000,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Borrowings outstanding		$ 0		$ 0		$ 0

FINANCING ARRANGEMENTS - Schedu

FINANCING ARRANGEMENTS - Schedule of Long-term Debt (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Principal value	$ 51,449	$ 38,886
Unamortized basis adjustment from swap terminations	76	82
Unamortized bond discounts and issuance costs	(405)	(303)
Unamortized purchase price adjustments of Celgene debt	847	872
Total	51,950	39,526
Current portion of Long-term debt	3,092	2,873
Long-term debt	48,858	36,653
Interest rate swap contracts
Debt Instrument [Line Items]
Fair value of interest rate swap contracts	$ (17)	$ (11)

FINANCING ARRANGEMENTS - Sche_2

FINANCING ARRANGEMENTS - Schedule of Senior Unsecured Notes In Public Offering (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Principal value	$ 51,449		$ 38,886
Basis spread on variable rate	0.49%
2024 Senior Unsecured Notes
Debt Instrument [Line Items]
Principal value		$ 13,000
Debt issuance costs, net		12,900
Floating rate notes due 2026
Debt Instrument [Line Items]
Principal value		500
$4.950% Notes due 2026
Debt Instrument [Line Items]
Principal value		$ 1,000
Interest rates		4.95%
$4.900% Notes due 2027
Debt Instrument [Line Items]
Principal value		$ 1,000
Interest rates		4.90%
$4.900% Notes due 2029
Debt Instrument [Line Items]
Principal value		$ 1,750
Interest rates		4.90%
$5.100% Notes due 2031
Debt Instrument [Line Items]
Principal value		$ 1,250
Interest rates		5.10%
$5.200% Notes due 2034
Debt Instrument [Line Items]
Principal value		$ 2,500
Interest rates		5.20%
$5.500% Notes due 2044
Debt Instrument [Line Items]
Principal value		$ 500
Interest rates		5.50%
$5.550% Notes due 2054
Debt Instrument [Line Items]
Principal value		$ 2,750
Interest rates		5.55%
$5.650% Notes due 2064
Debt Instrument [Line Items]
Principal value		$ 1,750
Interest rates		5.65%

RECEIVABLES - Schedule of Recei

RECEIVABLES - Schedule of Receivables (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Trade receivables	$ 10,471	$ 9,551
Less: charge-backs and cash discounts	(686)	(646)
Less: allowance for expected credit loss	(39)	(23)
Net trade receivables	9,746	8,882
Alliance, royalties, VAT and other	1,677	2,039
Receivables	$ 11,423	$ 10,921

RECEIVABLES (Details)

RECEIVABLES (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) customer	Jun. 30, 2023 USD ($)	Dec. 31, 2023 customer
Account Receivables [Line Items]
Non-U.S. receivables sold on a nonrecourse basis | $	$ 304	$ 503
Number of largest pharmaceutical wholesalers | customer	3		3
Customer Concentration Risk
Account Receivables [Line Items]
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers	74%		72%

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Inventory, Net [Abstract]
Finished goods	$ 862	$ 663
Work in process	2,807	2,430
Raw and packaging materials	437	475
Total inventories	4,106	3,568
Inventories	3,077	2,662
Other non-current assets	$ 1,029	$ 906

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Land	$ 162		$ 162		$ 162
Buildings	6,670		6,670		6,495
Machinery, equipment and fixtures	3,845		3,845		3,717
Construction in progress	1,255		1,255		1,075
Gross property, plant and equipment	11,932		11,932		11,449
Less accumulated depreciation	(5,087)		(5,087)		(4,803)
Property, plant and equipment	6,845		6,845		$ 6,646
Depreciation expense	$ 161	$ 151	$ 316	$ 297

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill [Roll Forward]
Balance at December 31, 2023	$ 21,169
Acquisitions (Note 4)	580
Currency translation and other adjustments	(17)
Balance at June 30, 2024	$ 21,732

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Other intangible assets
Accumulated amortization	$ (45,932)	$ (41,211)
Other intangible assets	29,428	27,072
Total	75,360	68,283
IPRD
Other intangible assets
Indefinite-lived intangible assets (excluding goodwill)	8,375	3,710
Other intangible assets	$ 8,375	3,710
R&D technology
Other intangible assets
Estimated useful lives (in years)	6 years
Gross carrying amounts	$ 1,980	0
Accumulated amortization	(110)	0
Other intangible assets	1,870	0
Acquired marketed product rights
Other intangible assets
Gross carrying amounts	63,473	63,076
Accumulated amortization	(44,726)	(40,184)
Other intangible assets	$ 18,747	22,892
Acquired marketed product rights | Minimum
Other intangible assets
Estimated useful lives (in years)	3 years
Acquired marketed product rights | Maximum
Other intangible assets
Estimated useful lives (in years)	15 years
Capitalized software
Other intangible assets
Gross carrying amounts	$ 1,532	1,497
Accumulated amortization	(1,096)	(1,027)
Other intangible assets	$ 436	$ 470
Capitalized software | Minimum
Other intangible assets
Estimated useful lives (in years)	3 years
Capitalized software | Maximum
Other intangible assets
Estimated useful lives (in years)	10 years

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Other intangible assets
Amortization of intangible assets	$ 2,400	$ 2,300	$ 4,800	$ 4,600
Impairment of intangible assets (excluding goodwill)				$ 20
Inrebic | Acquired marketed product rights
Other intangible assets
Impairment of intangible assets (excluding goodwill)	280
Investigational Compound for Hematologic Diseases | Celgene
Other intangible assets
Impairment of intangible assets (excluding goodwill)	$ 590

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Assets (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Supplemental Financial Information [Abstract]
Income taxes	$ 3,337	$ 3,927
Research and development	799	723
Contract assets	386	416
Restricted cash	2	55
Other	1,213	786
Other current assets	$ 5,737	$ 5,907

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Assets (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Supplemental Financial Information [Abstract]
Equity investments (Note 9)	$ 2,000	$ 1,699
Operating leases	1,316	1,390
Inventories (Note 12)	1,029	906
Pension and postretirement	210	284
Research and development	411	413
Restricted cash	1	0
Receivables and convertible notes	642	436
Other	462	242
Other non-current assets	$ 6,071	$ 5,370
Restricted cash for contributions and settlements			$ 53

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Supplemental Financial Information [Abstract]
Rebates and discounts	$ 7,686	$ 7,680
Income taxes	1,474	1,371
Employee compensation and benefits	921	1,291
Research and development	1,231	1,257
Dividends	1,217	1,213
Interest	591	349
Royalties	422	465
Operating leases	177	162
Other	2,264	2,096
Other current liabilities	$ 15,983	$ 15,884

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Supplemental Financial Information [Abstract]
Income taxes	$ 1,783	$ 3,288
Pension and postretirement	466	480
Operating leases	1,438	1,530
Deferred income	263	300
Deferred compensation	467	427
Contingent value rights	248	0
Other	328	396
Other non-current liabilities	$ 4,993	$ 6,421

EQUITY - Schedule of Stockholde

EQUITY - Schedule of Stockholders Equity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		$ 29,430			$ 29,430
Net earnings/(loss)	$ 1,684		$ 2,077		(10,224)	$ 4,344
Other comprehensive income/(loss)	(56)		$ (19)		90	$ (106)
Ending balance	$ 17,015				$ 17,015
Dividends declared (in usd per share)	$ 0.60	$ 0.60	$ 0.57	$ 0.57
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	2,923	2,923	2,923	2,923	2,923	2,923
Beginning balance	$ 292	$ 292	$ 292	$ 292	$ 292	$ 292
Ending balance (in shares)	2,923	2,923	2,923	2,923	2,923	2,923
Ending balance	$ 292	$ 292	$ 292	$ 292	$ 292	$ 292
Capital in Excess of Par Value of Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	45,655	45,684	45,140	45,165	45,684	45,165
Stock compensation	111	(29)	159	(25)
Ending balance	45,766	45,655	45,299	45,140	45,766	45,299
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	(1,400)	(1,546)	(1,368)	(1,281)	(1,546)	(1,281)
Other comprehensive income/(loss)	(56)	146	(19)	(87)
Ending balance	(1,456)	(1,400)	(1,387)	(1,368)	(1,456)	(1,387)
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	15,640	28,766	26,568	25,503	28,766	25,503
Net earnings/(loss)	1,680	(11,911)	2,073	2,262
Cash dividends declared	(1,217)	(1,215)	(1,192)	(1,197)
Ending balance	16,103	15,640	27,449	26,568	16,103	27,449
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (43,697)	$ (43,766)	$ (38,808)	$ (38,618)	$ (43,766)	$ (38,618)
Treasury stock, beginning balance (in shares)	896	902	823	825	902	825
Share repurchase program (in shares)			13	4
Share repurchase program			$ (911)	$ (250)
Stock compensation	$ 7	$ 69	$ 39	$ 60
Stock compensation (in shares)	0	(6)	(2)	(6)
Ending balance	$ (43,690)	$ (43,697)	$ (39,680)	$ (38,808)	$ (43,690)	$ (39,680)
Treasury stock, ending balance (in shares)	896	896	834	823	896	834
Noncontrolling Interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 58	$ 55	$ 62	$ 57	$ 55	$ 57
Net earnings/(loss)	4	3	4	5
Distributions	(8)		(9)
Ending balance	$ 54	$ 58	$ 57	$ 62	$ 54	$ 57

EQUITY - Schedule of Comprehens

EQUITY - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Equity [Abstract]
Unrealized (losses)/gains, pretax	$ 84	$ 94	$ 338	$ 81
Unrealized (losses)/gains, tax	(12)	(16)	(59)	(13)
Unrealized (losses)/gains, after tax	72	78	279	68
Reclassified to net earnings, pretax	(20)	(86)	(35)	(219)
Reclassified to net earnings, tax	2	11	1	30
Reclassified to net earnings, after tax	(18)	(75)	(34)	(189)
Derivatives qualifying as cash flow hedges, pretax	64	8	303	(138)
Derivatives qualifying as cash flow hedges, tax	(10)	(5)	(58)	17
Derivatives qualifying as cash flow hedges, after tax	54	3	245	(121)
Actuarial gains/(losses), pretax	(87)	(13)	(93)	(13)
Actuarial gains/(losses), tax	21	2	22	2
Actuarial gains/(losses), after tax	(66)	(11)	(71)	(11)
Amortization, pretax	1		3
Amortization, tax	0		0
Amortization, after tax	1		3
Settlements, pretax	0		19
Settlements, tax	1		(2)
Settlements, after tax	1		17
Pension and postretirement benefits, pre-tax	(86)		(71)
Pension and postretirement benefits, tax	22		20
Pension and postretirement benefits, after tax	(64)	(11)	(51)	(11)
Unrealized (losses)/gains on marketable debt securities, pretax	(1)		(3)
Unrealized (losses)/gains on marketable debt securities, tax	1		1
Unrealized (losses)/gains on marketable debt securities, after tax	0	0	(2)	0
Foreign currency translation, pretax	(37)	(4)	(81)	31
Foreign currency translation, tax	(9)	(7)	(21)	(5)
Foreign currency translation, after tax	(46)	(11)	(102)	26
Other comprehensive income, pre-tax	(60)	(9)	148	(120)
Other comprehensive income, tax	4	(10)	(58)	14
Total Other Comprehensive Income/(Loss)	$ (56)	$ (19)	$ 90	$ (106)

EQUITY - Schedule of Accumulate

EQUITY - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Derivatives qualifying as cash flow hedges	$ 247	$ 2
Pension and postretirement benefits	(789)	(738)
Marketable debt securities	0	2
Foreign currency translation	(914)	(812)
Accumulated other comprehensive loss	(1,456)	(1,546)
Net investment hedge gains	$ 215	$ 144

EMPLOYEE STOCK BENEFIT PLANS -

EMPLOYEE STOCK BENEFIT PLANS - Stock Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Stock-based compensation expense	$ 125	$ 137	$ 258	$ 259
Income tax benefit	27	27	55	52
Excess tax benefits from share-based compensation awards	(3)	2	(20)	20
Cost of products sold
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Stock-based compensation expense	14	13	28	24
Marketing, selling and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Stock-based compensation expense	48	56	101	107
Research and development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Stock-based compensation expense	$ 63	$ 68	$ 129	$ 128

EMPLOYEE STOCK BENEFIT PLANS _2

EMPLOYEE STOCK BENEFIT PLANS - Schedule of Share-based Compensation Additional Information (Details) shares in Millions	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units granted (in shares) | shares	13
Weighted-average fair value (in usd per share) | $ / shares	$ 47.54
Market share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units granted (in shares) | shares	1.3
Weighted-average fair value (in usd per share) | $ / shares	$ 58.63
Performance share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units granted (in shares) | shares	1.9
Weighted-average fair value (in usd per share) | $ / shares	$ 53.08

EMPLOYEE STOCK BENEFIT PLANS _3

EMPLOYEE STOCK BENEFIT PLANS - Share-based Payment Arrangement, Nonvested Award, Cost (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,075
Expected weighted-average period in years of compensation cost to be recognized	2 years 10 months 24 days
Market share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	$ 90
Expected weighted-average period in years of compensation cost to be recognized	2 years 7 months 6 days
Performance share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	$ 123
Expected weighted-average period in years of compensation cost to be recognized	2 years 1 month 6 days

LEGAL PROCEEDINGS AND CONTING_2

LEGAL PROCEEDINGS AND CONTINGENCIES (Details) $ in Millions, $ in Millions

1 Months Ended

2 Months Ended

May 21, 2024 USD ($)

Mar. 31, 2024 plaintiff

Dec. 31, 2023 defendant plaintiff

Feb. 28, 2021 USD ($)

Mar. 31, 2010 AUD ($)

Mar. 31, 2010 USD ($)

Nov. 30, 2023 healthcare_system lawsuit

Jun. 30, 2024 USD ($) lawsuit

Nov. 30, 2022 lawsuit

Jun. 30, 2022 claim

Apr. 01, 2022

Nov. 30, 2021 acquirer lawsuit

Jun. 30, 2021 USD ($)

Mar. 31, 2018 lawsuit

Legal Proceedings And Contingencies [Line Items]

Damages sought | $

$ 916

$ 834

Class action claims

2

Obligation to holders of the contingent value rights | $

$ 6,400

Number of healthcare systems | healthcare_system

3

Running royalty

0.015

Accrued liabilities for CERCLA matters | $

$ 77

Bristol-Myers Squibb

Legal Proceedings And Contingencies [Line Items]

Damages sought | $

$ 458

$ 417

Plavix Australia Intellectual Property

Legal Proceedings And Contingencies [Line Items]

Damages paid

$ 449

$ 298

Abilify Product Liability | NEW JERSEY

Legal Proceedings And Contingencies [Line Items]

Individual injury claims

11

Abilify Product Liability | CANADA

Legal Proceedings And Contingencies [Line Items]

Individual injury claims

7

Pending claims

11

Class action claims

4

Pending claims, active

2

Celgene Securities Class Action

Legal Proceedings And Contingencies [Line Items]

Putative claims

2

Celgene Contingent Value Rights

Legal Proceedings And Contingencies [Line Items]

Putative claims

2

Number of acquirers | acquirer

1

Molina Litigation

Legal Proceedings And Contingencies [Line Items]

Class action claims | claim

63

Dismissed cases | claim

4

Opt-Out Entities

Legal Proceedings And Contingencies [Line Items]

Class action claims

2

Mayo Clinic, LifePoint Corporate Services, and Intermountain Health

Legal Proceedings And Contingencies [Line Items]

Class action claims

2

Pomalyst Antitrust Class Action

Legal Proceedings And Contingencies [Line Items]

Number of plaintiffs | plaintiff

1

1

Loss contingency, number of defendants | defendant

2